Protein degradation inhibitors for improved production
By contacting the cells with protein degradation inhibitors, evaluating and selecting cell lines with improved productivity, the problem of low production efficiency of recombinant proteins in the prior art is solved, and high yield and high quality protein production is achieved.
Patent Information
- Application Number
- CN202410975316.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-01-08
- Filing Date
- 2017-01-06
- Publication Date
- 2024-11-08
AI Technical Summary
It is difficult to effectively select and identify recombinant protein production cell lines with high yields, especially recombinant CHO cell lines, resulting in inefficient protein production.
By contacting cells with protein degradation inhibitors, the activity of protein degradation pathways is identified and selected by evaluating and selecting cells with improved productivity, such as using proteasome inhibitors, ubiquitin pathway inhibitors and ERAD inhibitors, thereby decreasing the activity of protein degradation pathways, thereby identifying and selecting high yields. cell line.
It significantly improves the productivity and quality of recombinant proteins, increases the yield and correct folding ratio of recombinant peptides, reduces unnecessary isoforms and fragmented forms, and improves cell function and enzyme activity of products.
Smart Images

Figure CN118909952A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese invention patent application with the application date of January 6, 2017, application number: 201780012368.1, and invention name: "Protein degradation inhibitors for improved production".
[0002] This application claims priority to U.S. Application No. 62 / 275,961, filed January 6, 2016; and U.S. Application No. 62 / 276,339, filed January 8, 2016, the entire contents of each of which are incorporated herein by reference. Technical Field
[0003] The present disclosure relates to cells and cell lines, such as eukaryotic cells and cell lines, for producing products, such as recombinant proteins. The present disclosure also relates to regulating protein degradation pathways to achieve improved production of products, such as recombinant proteins. Background Art
[0004] The generation and selection of highly productive recombinant CHO cell lines has been highlighted as a bottleneck in the cell line development process. Therefore, methods are needed to identify and generate cell lines with the ability to highly produce recombinant proteins. Summary of the invention
[0005] The present disclosure is based in part on the following findings: the correlation between the ability of cells, such as eukaryotic cells, such as eukaryotic cells, such as mammals or cells other than mammalian cells to produce products, such as recombinant polypeptides, and susceptibility to protein degradation pathway inhibitors, such as proteasome inhibitors, ubiquitin pathway inhibitors, and ERAD inhibitors. Without wishing to be bound by theory, it is believed that protein degradation pathway inhibitors can be used to select highly productive cells, such as cells capable of producing products, such as high yields of recombinant polypeptides. Therefore, methods and processes for evaluating, selecting, classifying or identifying cells for producing products (such as recombinant polypeptides) are disclosed herein. Methods and methods for generating cells or cell lines for producing products (such as recombinant polypeptides) by identifying or selecting cells capable of high productivity are also provided herein. These methods and processes described herein include contacting cells with protein degradation inhibitors, such as inhibiting or reducing the activity of protein degradation pathways. Therefore, not only is provided herein for identifying better quality cells, such as having higher productivity, for producing products, such as recombinant polypeptides, but also cells producing better quality products, such as recombinant polypeptide products, such as monoclonal antibodies and difficult-to-express proteins, such as bispecific molecules.
[0006] In one aspect, the disclosure features methods of evaluating, classifying, identifying, generating, or selecting cells or progeny cells or a population of progeny cells, e.g., for producing a product, e.g., a polypeptide, a recombinant polypeptide. In one embodiment, the method includes:
[0007] a) optionally providing cells;
[0008] b) contacting the cell (or a descendant of the cell) with a protein degradation inhibitor, such as a proteasome inhibitor, a ubiquitin pathway inhibitor, or an endoplasmic reticulum-associated degradation (ERAD) inhibitor;
[0009] c) evaluating the effect of a protein degradation inhibitor, such as a proteasome inhibitor, a ubiquitin pathway inhibitor or an ERAD inhibitor, on one or more parameters associated with cellular function in said cell (or a progeny of said cell);
[0010] d) optionally comparing the value of the effect of a protein degradation inhibitor, such as a proteasome inhibitor, on said one or more parameters with a reference value; and
[0011] e) optionally expressing a product, such as a recombinant polypeptide, from the cell (or progeny of the cell); and
[0012] Thereby evaluating, classifying, identifying, generating or selecting cells or progeny cells or progeny cell populations. In one embodiment, the method comprises providing cells. In one embodiment, the method comprises comparing the effect of a protein degradation inhibitor (e.g., a proteasome inhibitor) on one or more parameters with a reference value. In one embodiment, the method comprises expressing a product, such as a recombinant polypeptide, from a cell (or the progeny of a cell).
[0013] The product produced by the cells and methods described herein can be a molecule, nucleic acid, polypeptide or any fusion or heterocomplex thereof. In one embodiment, the product is a non-natural substance or molecule. In another embodiment, the product is a naturally occurring substance or molecule. The cell that produces the product described herein is engineered or modified to control, for example, increase expression, or to produce, for example, to encode the product described herein. In one embodiment, the cell is engineered or modified to include an exogenous nucleic acid that controls, for example, increases the expression of an endogenously expressed product. In another embodiment, the cell is engineered or modified to include an exogenous nucleic acid that encodes a product, for example, an endogenously expressed product, a product that is not endogenously produced by the cell, or a non-naturally occurring product.
[0014] In one embodiment, a method of evaluating, classifying, identifying, generating or selecting a cell or progeny cell or a population of progeny cells, e.g., for producing a product, e.g., a polypeptide, a recombinant polypeptide, comprises evaluating a cell or a progeny cell or a population of progeny cells.
[0015] In one embodiment, a method of evaluating, classifying, identifying, generating or selecting a cell or progeny cell or a population of progeny cells, e.g., for producing a product, e.g., a polypeptide, a recombinant polypeptide, comprises classifying a cell or a progeny cell or a population of progeny cells.
[0016] In one embodiment, a method of evaluating, classifying, identifying, generating or selecting a cell or a progeny cell or a population of progeny cells, e.g., for producing a product, e.g., a polypeptide, a recombinant polypeptide, comprises identifying a cell or a progeny cell or a population of progeny cells.
[0017] In one embodiment, a method of evaluating, classifying, identifying, generating or selecting a cell or progeny cell or a population of progeny cells, e.g., for producing a product, e.g., a polypeptide, a recombinant polypeptide, comprises generating a cell or a progeny cell or a population of progeny cells.
[0018] In one embodiment, a method of evaluating, classifying, identifying, generating or selecting a cell or progeny cell or a population of progeny cells, e.g., for producing a product, e.g., a polypeptide, a recombinant polypeptide, comprises selecting a cell or a progeny cell or a population of progeny cells.
[0019] In one embodiment, the method of evaluating, classifying, identifying, generating or selecting a cell or progeny cell or a population of progeny cells for, e.g., producing a product, e.g., a polypeptide, a recombinant polypeptide, further comprises, e.g., as part of step (b), culturing the cell (or the progeny of the cell) contacted with the protein degradation inhibitor.
[0020] The methods herein include identifying or selecting cells with improved, e.g., increased productivity, e.g., the ability to produce a product, e.g., a polypeptide, e.g., a recombinant polypeptide. In one embodiment, the level, amount, or quantity of the product produced by the identified or selected cells is increased, e.g., 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-fold or more compared to the level, amount, or quantity produced by cells not yet contacted with a protein degradation inhibitor.
[0021] Methods described herein include identifying or selecting cells with improved, e.g., increased, products, such as recombinant polypeptide quality. In one embodiment, the quality of the product produced by the identified or selected cells is increased by, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or 100 times or more, compared to the quality of the product produced by cells that have not yet been contacted by a protein degradation inhibitor. In one embodiment, the improvement in product quality includes one or more of the following: the level, amount, or ratio of the desired product increases, e.g., relative to an unwanted isoform, fragmentation, or truncated form; the level, amount, or ratio of the correctly folded product increases; functionality, such as an increase in the level, number, or ratio of an enzymatically active product; the level, amount, or ratio of the aggregated product decreases; or the level, amount, or ratio of a fragmented or unwanted isoform decreases.
[0022] In one embodiment, the method of evaluating, classifying, identifying, generating or selecting for, for example, producing a product, such as a cell or progeny cell or progeny cell colony of a polypeptide, a recombinant polypeptide includes comparing the effect value of a protein degradation inhibitor (e.g., a proteasome inhibitor) with a reference value. In embodiments where the value has a predetermined relationship with the reference value, the method includes classifying or selecting cells or progeny cells or progeny cell colonies, such as for establishing a culture, such as a cell merger. In some embodiments where the value meets or exceeds the reference value, the method includes classifying or selecting progeny or progeny cells or progeny cell colonies, such as for establishing a culture, such as a cell merger or for producing a polypeptide, such as a recombinant polypeptide. In embodiments where the value has a predetermined relationship with the reference value, the method includes classifying or selecting progeny or progeny cells or progeny cell colonies, such as for producing a polypeptide, such as a recombinant polypeptide. In embodiments where the value meets or exceeds the reference value, cells or progeny cells or progeny cell colonies are classified, identified or selected as production cells or progeny cells or progeny cell colonies. In some embodiments where the value has a predetermined relationship with the reference value, the method includes selecting cells (or progeny of cells), such as for generating cell lines or cell colonies.
[0023] In one embodiment, parameters associated with cell function include, for example, selected from:
[0024] i) cell survival,
[0025] ii) Cultivate viability,
[0026] iii) the ability to produce a product, such as a polypeptide, such as a recombinant polypeptide,
[0027] iv) proteasome activity; or
[0028] v) The quality of the expression product, e.g., a polypeptide, e.g., a recombinant polypeptide, e.g., a more homogeneous product.
[0029] In one embodiment, the method comprises evaluating more than one parameter. In one embodiment, the method comprises evaluating more than one parameter and comparing the measured parameters to a reference value.
[0030] Also provided herein is a method for establishing a cell line from the offspring cells of a cell or a cell described herein. In one embodiment, the method also includes culturing cells to provide a cultured cell colony, such as an offspring cell colony. In one embodiment, the method also includes selecting cells from a cultured cell colony, such as an offspring cell colony. In one embodiment, the method includes evaluating the parameter associated with cell function to the selected cell (or offspring of a cell), for example, providing the value of a parameter, such as a parameter associated with cell function as described herein. In these embodiments where the value has a predetermined relationship with a reference value, select cells (or offspring of a cell), for example, for producing polypeptides, such as recombinant polypeptides. In embodiments where the value meets or exceeds a reference value, select cells (or offspring of a cell) as production cells. In one embodiment, the method also includes setting up a cell line from the cell.
[0031] In one embodiment, for example, the method of evaluating, classifying, identifying, generating or selecting a cell or progeny cell or progeny cell colony for, for example, producing a product, such as a polypeptide, a recombinant polypeptide, also includes introducing an exogenous nucleic acid into a cell. In one embodiment, the exogenous nucleic acid encodes a product, such as a recombinant polypeptide, or controls, for example, an exogenous nucleic acid that increases the expression of a product (e.g., an endogenous polypeptide). In one embodiment, the exogenous nucleic acid is introduced after one or more of steps a), b), c) and d). In one embodiment, the exogenous nucleic acid is introduced before one or more of steps a), b), c) and d). In one embodiment, the exogenous nucleic acid encodes a polypeptide, such as a recombinant polypeptide, such as a therapeutic polypeptide or an antibody molecule selected from Table 1 or 2. In one embodiment, the method also includes introducing one or more additional exogenous nucleic acids (e.g., a second exogenous nucleic acid) into a cell. In one embodiment, the second exogenous nucleic acid is introduced after one or more of steps a), b), c) and d). In one embodiment, the second exogenous nucleic acid is introduced before one or more of steps a), b), c) and d). In one embodiment, the second exogenous nucleic acid is introduced after the first exogenous nucleic acid is introduced. In one embodiment, the second exogenous nucleic acid is introduced before the first exogenous nucleic acid is introduced. In one embodiment, the second exogenous nucleic acid is introduced simultaneously with the first exogenous nucleic acid. In one embodiment, the second exogenous nucleic acid encodes a selection marker, such as glutamine synthase. In one embodiment, the method further comprises introducing the exogenous nucleic acid, including transfection, electroporation or transduction.
[0032] In one embodiment, for example, the method of evaluating, classifying, identifying, generating or selecting for, for example, producing a product, such as a polypeptide, a recombinant polypeptide, a progeny cell or a progeny cell population also includes evaluating a second characteristic of the cell, for example, determining whether the cell comprises an exogenous component, for example, one or more exogenous nucleic acids, such as one or more exogenous nucleic acids integrated into the cell nucleic acid, such as one or more exogenous nucleic acids integrated into the chromosome genome of the cell. In one embodiment, the method includes determining whether the cell comprises one or more exogenous nucleic acids integrated into the cell nucleic acid, such as one or more exogenous nucleic acids integrated into the chromosome genome of the cell, including MSX selection, MTX selection (such as DHFR system), antibiotic selection, yeast growth selection, selection based on color change or surface expression of markers, selection based on the Selexis system, or selection based on the Catalant system. In one embodiment, antibiotic selection includes selecting resistance to an antibiotic selected from hygromycin, neomycin (G418), zeocin, puromycin or blasticidin.
[0033] In one embodiment, the method of evaluating, classifying, identifying, generating or selecting cells or progeny cells or progeny cell populations for, e.g., producing products, e.g., polypeptides, recombinant polypeptides, comprises evaluating the effect of a protein degradation inhibitor (e.g., a proteasome inhibitor) on parameters associated with cell function (e.g., survival, viability, or proliferation capacity, or producing products, e.g., polypeptides, e.g., polypeptides expressed by exogenous nucleic acids); and, e.g., by MSX selection, determining whether the cell contains an exogenous nucleic acid integrated into the chromosomal genome of the cell. In one embodiment, wherein in response to the evaluation of the effect of the protein degradation inhibitor in the step and the step of determining whether the cell contains an exogenous nucleic acid integrated into the chromosomal genome of the cell, the cell, progeny cell or progeny cell population is evaluated, classified, identified or selected.
[0034] In one embodiment, the method of evaluating, classifying, identifying, generating or selecting for, for example, producing a product, such as a polypeptide, a recombinant polypeptide, a cell or a progeny cell or a progeny cell colony also includes an additional selection step, such as by FACS selection, magnetic separation, such as magnetic beads, colony selection, microfluidic cell sorting or microfluidic cell destruction. In embodiments, the selection step includes determining whether the cell comprises one or more exogenous nucleic acids. In embodiments, the selection step includes determining whether the cell comprises one or more exogenous nucleic acids integrated into the cell nucleic acid, such as one or more exogenous nucleic acids integrated into the chromosome genome of the cell.
[0035] In one embodiment, the method of evaluating, classifying, identifying, generating or selecting a cell or progeny cell or a progeny cell population for, for example, producing a product, such as a polypeptide, a recombinant polypeptide, further comprises introducing into the cell an agent that assists protein folding, such as a chaperone molecule or a small chemical molecule. In one embodiment, the agent that assists protein folding comprises a nucleic acid encoding a chaperone or a component of a protein folding pathway, such as XBP1, SRP14, BiP / GRP78, PDI, calnexin or cyclophilin B. In one embodiment, the agent that assists protein folding comprises a small molecule selected from DMSO, glycerol or PBA.
[0036] In another aspect, the invention features methods for generating cell lines or cell colonies, including identifying cells by the methods herein; and culturing cells or cell colonies to provide cell lines or cell colonies. In another aspect, the invention features methods for generating cell lines or cell colonies, including identifying or selecting cells by the methods described; and culturing cells or cell colonies to provide cell lines or cell colonies.
[0037] In another aspect, the invention features a method of producing a product (e.g., a polypeptide, e.g., a recombinant polypeptide) comprising: providing a cell or a cell population produced by a method described herein; culturing the cell or cell population in culture; and, optionally, recovering the product, e.g., a polypeptide, e.g., a recombinant polypeptide, from the cell or the culture medium in which the cells are cultured.
[0038] In another aspect, the disclosure features a cell, progeny cell, or population of progeny cells assessed, classified, or selected by any of the methods described herein.
[0039] In another aspect, the invention features a cell, progeny cell, or population of progeny cells produced by any of the methods described herein.
[0040] In another aspect, the disclosure features a cell, progeny cell, or population of progeny cells, which can be generated by any of the methods described herein.
[0041] In another aspect, the disclosure features a product, eg, a polypeptide, eg, a recombinant polypeptide, produced or producible by any of the methods described herein or any of the cells described herein.
[0042] In another aspect, the disclosure features a preparation containing a product described herein, e.g., a product produced or producible by any method described herein or any cell described herein, e.g., a polypeptide, e.g., a recombinant polypeptide.
[0043] In another aspect, the invention features a mixture comprising a cell described herein and a product, eg, a polypeptide, eg, a recombinant polypeptide, described herein.
[0044] In another aspect, the disclosure features a preparation of culture medium conditioned by culturing a cell, progeny cell, or a population of progeny cells described herein, eg, a cell, progeny cell, or a population of progeny cells described herein.
[0045] In another aspect, the invention features a method of generating a cell or cell progeny that produces a recombinant protein (e.g., a recombinant therapeutic protein, e.g., a recombinant therapeutic antibody), comprising:
[0046] a) optionally, providing cells;
[0047] b) culturing the cell or progeny of the cell (e.g., for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 or more generations or for at least 12, 24, 48, 72 hours or 1, 2, 4, 8, 16, 32 or more weeks) in the presence of an exogenous protein degradation inhibitor, such as a proteasome inhibitor, an ubiquitin pathway inhibitor, or an endoplasmic reticulum-associated degradation (ERAD) inhibitor;
[0048] c) culturing the cell or cell progeny in the absence of the exogenous protein degradation inhibitor (e.g., for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more generations or for at least 12, 24, 48, 72 hours);
[0049] d) optionally, evaluating the effect of the protein degradation inhibitor on the level of recombinant protein produced by the cell or the progeny of the cell, e.g., to obtain a value for the recombinant protein produced by the cell or the progeny of the cell; and
[0050] e) optionally, comparing the value obtained in d) with a reference value, wherein the reference value is the level of the recombinant protein produced by cells of the same type as the cells provided in a) cultured in the absence of the exogenous protein degradation inhibitor;
[0051] The cell or cell progeny is thereby generated.
[0052] Other features or embodiments of any of the methods or compositions described herein include one or more of the following:
[0053] Protein degradation inhibitors
[0054] In the embodiments of any method or composition described herein, the protein degradation inhibitor is a proteasome inhibitor. In one embodiment, the proteasome inhibitor inhibits or reduces the activity of one or more of the 20S core subunit, 19S regulatory subunit, 11S regulatory particle or auxiliary proteasome assembly chaperones, such as Hsm3 / S5b, Nas2 / p27, Rpn14 / PAAF1 and Nas6 / oncogenic ankyrin repeats. In one embodiment, the proteasome inhibitor is selected from MG132 (Z-LLL-al, Z-Leu-Leu-Leu-al, Z-Leu-Leu-Leu-CHO), epoxomicin, bortezomib, ixazomib, carfilzomib, disulfiram, CEP-18770, ONX 0912, salt spore amide, LLnV, CEP1612, lactacystin, PS-341 and eponomicin.
[0055] In the embodiments of any method or composition described herein, the protein degradation inhibitor is an ERAD inhibitor. In one embodiment, the ERAD inhibitor inhibits or reduces the activity of one or more of the following: calnexin / calreticulin, UDP-glucose-glycoprotein glucosyltransferase, ER degradation enhancing α-mannosidase-like protein (EDEM), ER mannosidase I, Sec61, CDC48p (VCP / p97), Hrd1, Doa10, Ubc6, Ubc1, Cue1, or Ubc7. In one embodiment, the protein degradation inhibitor is eeyarestatin I.
[0056] In an embodiment of any of the methods or compositions described herein, the protein degradation inhibitor is an ubiquitin pathway inhibitor. In one embodiment, the ubiquitin pathway inhibitor inhibits or reduces the activity of one or more of: an E1 ubiquitin activating enzyme, an E2 ubiquitin conjugating enzyme, or an E3 ubiquitin ligase.
[0057] In an embodiment of any method described herein, the method further comprises contacting the candidate cell with a second protein degradation inhibitor, such as a proteasome inhibitor, an ERAD inhibitor, or a ubiquitin pathway inhibitor. In one embodiment, the cell is contacted with the first and second protein degradation inhibitors, such as simultaneously or sequentially. In one embodiment, the first protein degradation inhibitor and the second protein degradation inhibitor are selected from MG132, epoxomicin, or eeyarestatin 1. In one embodiment, the cell is contacted with the first and second protein degradation inhibitors, such as simultaneously or sequentially, and the first inhibitor is a proteasome inhibitor, and the second inhibitor is a proteasome inhibitor. In one embodiment, the cell is contacted with the first and second protein degradation inhibitors, such as simultaneously or sequentially, and the first inhibitor is a proteasome inhibitor, and the second inhibitor is an ERAD inhibitor or a ubiquitin pathway inhibitor. In one embodiment, the cell is contacted with the first and second inhibitors of protein degradation, such as simultaneously or sequentially, and the first inhibitor is an ERAD inhibitor, and the second inhibitor is an ERAD inhibitor. In an embodiment, the first inhibitor is different from the second inhibitor. In one embodiment, the cell is contacted with the first and second protein degradation inhibitors, such as simultaneously or sequentially, and the first inhibitor is an ERAD inhibitor, and the second inhibitor is a ubiquitin pathway inhibitor or a proteasome inhibitor. In one embodiment, the cell is contacted with a first and a second inhibitor of protein degradation, e.g., simultaneously or sequentially, and the first inhibitor is a ubiquitin pathway inhibitor and the second inhibitor is a ubiquitin pathway inhibitor. In one embodiment, the cell is contacted with a first and a second inhibitor of protein degradation, e.g., simultaneously or sequentially, and the first inhibitor is a ubiquitin pathway inhibitor and the second inhibitor is an ERAD or proteasome inhibitor.
[0058] In the embodiments of any method described herein, cells are contacted with a concentration of a protein degradation inhibitor, the concentration being sufficient to reduce the culture viability by about 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, 80%, 85%, 90%, 95%, for example, compared to the culture viability before contacting the culture with the inhibitor, or compared to a culture not contacted with the inhibitor. In one embodiment, the concentration of the protein degradation inhibitor is less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, or 0.05% of the total cells survive in culture after contacting the protein degradation inhibitor. In one embodiment, the concentration of the protein degradation inhibitor is a concentration at which one or more cells continue to proliferate. In one embodiment, the concentration of the protein degradation inhibitor is less than 0.5 μM MG-132. In one embodiment, the concentration of the protein degradation inhibitor is about 0.0625 μM MG-132. In one embodiment, the concentration of the protein degradation inhibitor is less than 0.05 μM epoxomicin. In one embodiment, the concentration of the protein degradation inhibitor is about 0.025 μM epoxomicin. In one embodiment, the concentration of the protein degradation inhibitor is a low concentration of eeyarestatin I, such as 0.1 μM. In one embodiment, the concentration of the protein degradation inhibitor is less than 0.5 μM eeyarestatin I, such as about 0.1 μM eeyarestatin I.
[0059] In embodiments of any of the methods described herein, the cells are contacted with the protein degradation inhibitor for 24, 48, 72, 96, or 168 hours. In embodiments of any of the methods described herein, the cells (or progeny of the cells) are cultured in the presence of the protein degradation inhibitor for 24, 48, 72, 96, hours or more. In embodiments of any of the methods described herein, the cells (or progeny of the cells) are cultured in the presence of the protein degradation inhibitor for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 generations or more or at least 12, 24, 48, 72 hours. In embodiments of any of the methods described herein, the cells are contacted with the protein degradation inhibitor for 24, 48, 72, 96, or 168 hours after the selection step, e.g., MSX selection. In embodiments of any of the methods described herein, the cells are contacted with the protein degradation inhibitor for 24, 48, 72, 96, or 168 hours before the selection step, e.g., MSX selection. In embodiments of any of the methods described herein, the cells are contacted with a protein degradation inhibitor simultaneously or concurrently with the selection step (eg, MSX selection).
[0060] cell
[0061] In some embodiments of any of the methods or compositions described herein, the method includes providing a cell that expresses a polypeptide, e.g., a recombinant polypeptide, e.g., a cell that contains an exogenous nucleic acid that encodes a product, e.g., a polypeptide, e.g., a recombinant polypeptide, or controls expression of a polypeptide, e.g., a recombinant polypeptide.
[0062] In the embodiments of any method or composition described herein, the cell comprises an exogenous nucleic acid encoding a product, such as a polypeptide, such as a recombinant polypeptide or controlling, for example, an increase in a polypeptide, such as the expression of a recombinant polypeptide. In embodiments, the exogenous nucleic acid comprises a nucleic acid sequence encoding one or more (e.g., two) recombinant polypeptides. In one embodiment, the cell is a cell that has been used commercially to produce a polypeptide product, a cell that has been used to produce a type of polypeptide for preclinical work, or a cell that has been used to produce a product (e.g., a polypeptide) for clinical trials. In one embodiment, the cell expresses a polypeptide, such as a recombinant polypeptide, selected from Table 1 or 2.
[0063] In the embodiments of any method or composition described herein, the cell is a eukaryotic cell. In one embodiment, the cell is a mammalian cell. In one embodiment, the cell is from a mouse, a rat, a Chinese hamster, a Syrian hamster, a monkey, an ape (e.g., including a human), a dog, a horse, a camel, a ferret, or a cat. In one embodiment, the cell is a CHO cell, such as CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHODXB11, CHOZN, or a CHO derived cell. In one embodiment, the cell is selected from HeLa, HEK293, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK, VERO, SP2 / 0, NS0, YB2 / 0, EB66, C127, L cells, COS, such as COS1 and COS7, QC1-3, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, and CHOZN.
[0064] In embodiments of any of the methods or compositions described herein, the cell is a eukaryotic cell other than a mammalian cell. In one embodiment, the cell is from an insect, a plant, a duck, a parrot, a fish, a yeast or a fungus.
[0065] product
[0066] As described herein, the product produced by the cells and methods of the present disclosure can be a molecule, a nucleic acid, a polypeptide, or any fusion or heterocompound thereof. In one embodiment, the product is a non-natural substance or molecule. In another embodiment, the product is a naturally occurring substance or molecule. The cell that produces the product described herein is engineered or modified to control, for example, increase expression, or to produce, for example, encode the product described herein. In one embodiment, the cell is engineered or modified to include an exogenous nucleic acid that controls, for example, increases the expression of an endogenously expressed product. In another embodiment, the cell is engineered or modified to include an exogenous nucleic acid that encodes a product, such as an endogenously expressed product, a product that is not endogenously produced by the cell, or a non-naturally occurring product.
[0067] In one embodiment, the product, e.g., a polypeptide, e.g., a recombinant polypeptide, is a therapeutic polypeptide, e.g., for administration to a subject suffering from a disease or disorder. In one embodiment, the product, e.g., a polypeptide, e.g., a recombinant polypeptide, is a diagnostic polypeptide.
[0068] In any of the methods or compositions disclosed herein, the product comprises one or more of an antibody molecule, a bispecific molecule, a coagulation factor, an anticoagulant, a hormone, an interferon, an interleukin, or an enzyme.
[0069] In one embodiment, the product comprises an antibody molecule, such as a full-length antibody or an antibody fragment. In one embodiment, the product comprises an antibody molecule or a fragment thereof coupled to a second reagent (e.g., a polypeptide, such as a toxin), such as a covalent or non-covalently coupled antibody molecule. In one embodiment, the antibody molecule is a monoclonal antibody. In one embodiment, the antibody molecule binds to a tumor or cancer-associated antigen. In one embodiment, the antibody molecule binds to a tumor-associated glycoprotein (TAG72). In one embodiment, the product comprises a bispecific molecule, such as the bispecific molecule provided in Table 2.
[0070] In one embodiment, the product, eg, a polypeptide, eg, a recombinant polypeptide, is a human polypeptide whose amino acid sequence does not differ from a naturally occurring isoform of the human polypeptide.
[0071] In another embodiment, the product, e.g., polypeptide, e.g., recombinant polypeptide, differs from a naturally occurring isoform of the human polypeptide by no more than 1, 2, 3, 4, 5, 10, 15, or 20 amino acid residues.
[0072] In another embodiment, the product, e.g., a polypeptide, e.g., a recombinant polypeptide, differs from a naturally occurring isoform of a human polypeptide or protein by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 15% of its amino acid residues.
[0073] In any of the methods or compositions disclosed herein, the product comprises a polypeptide, e.g., a recombinant polypeptide, selected from Table 1 or Table 2. In one embodiment, the product, e.g., a polypeptide, e.g., a recombinant polypeptide, is a polypeptide from Table 1 or Table 2.
[0074] In another embodiment, the product, e.g., a polypeptide, e.g., a recombinant polypeptide, differs from a polypeptide of Table 1 or Table 2 by no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues.
[0075] In another embodiment, the product, e.g., a polypeptide, e.g., a recombinant polypeptide, differs from a polypeptide from Table 1 or Table 2 by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 15% of its amino acid residues.
[0076] In any method or composition as described herein, the exogenous nucleic acid comprising the nucleic acid sequence of the control product expression encoding product (e.g., recombinant polypeptide) is introduced into the cell. In any method or composition as described herein, the cell comprises exogenous nucleic acid, which comprises the nucleic acid sequence of the encoding product, e.g., recombinant polypeptide. In one embodiment, the exogenous nucleic acid is integrated into the nucleic acid in the cell, e.g., the chromosomal genome of the cell. In another embodiment, the exogenous nucleic acid is not integrated into the chromosomal genome of the cell, but is integrated on an artificial chromosome or a plasmid, e.g., so that the exogenous nucleic acid is maintained in the cell or the offspring of the cell.
[0077] In any of the methods or compositions described herein, the exogenous nucleic acid can further comprise one or more, e.g., two, three, four or five additional nucleic acid sequences, e.g., encoding a product or other sequences or polypeptides to control expression of a product.
[0078] In any method or composition described herein, the exogenous nucleic acid comprises a plasmid or vector, such as an expression or viral vector. In one embodiment, the exogenous nucleic acid comprises a glutamine synthase (GS) expression vector. In one embodiment, the exogenous nucleic acid also comprises a nucleic acid sequence encoding a selection marker. In one embodiment, the selection marker comprises a gene that glutamine synthase, DHFR or confer antibiotic resistance. In one embodiment, the nucleic acid sequence encoding the selection marker is operably connected to the first promoter, and the encoding product, such as a polypeptide, such as a nucleic acid sequence of a recombinant polypeptide is operably connected to the second promoter. In one embodiment, the first promoter and the second promoter are different. In one embodiment, the promoter operably connected to the selection marker is a weak promoter, such as an SV40E promoter. In one embodiment, the promoter operably connected to the nucleic acid sequence encoding a polypeptide, such as a recombinant polypeptide is a strong promoter, such as a CMV promoter, such as an hCMV-MIE promoter.
[0079] In any method described herein, the method comprises expressing a product, such as a polypeptide, such as a recombinant polypeptide, from a cell or progeny cell. In one embodiment, the product, such as a polypeptide, such as a recombinant polypeptide, is secreted from the cell or progeny cell into, for example, a culture medium.
[0080] In any of the methods or compositions described herein, an expressed product, e.g., a polypeptide, e.g., a recombinant polypeptide, is evaluated for a parameter associated with a physical or functional property, e.g., primary sequence, glycosylation, primary, secondary, tertiary, or quaternary structure, activity, degree of glycosylation, degree of aggregation, the proportion or level of expression product having a preselected property, e.g., having a preselected monomeric, dimeric, or trimeric structure, or the level or proportion of expression product having a preselected structure, e.g., a non-denatured or non-aggregated structure. In embodiments, the method comprises providing a value for the parameter. In embodiments, the method comprises comparing the value of the parameter to a reference value.
[0081] In embodiments of any method or composition described herein, the value of the effect of a protein degradation inhibitor (e.g., a proteasome inhibitor) on a parameter associated with a cell function exceeds a reference value by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more. In embodiments, the value of the effect of a protein degradation inhibitor (e.g., a proteasome inhibitor) on a parameter associated with a cell function exceeds a reference value by 1, 2, 3, 4, 5, 6, 7, or 8 times or more. In embodiments, the reference value is the value of the effect of a protein degradation inhibitor on a parameter associated with a cell function of a reference cell or on a parameter associated with a cell function that has not been contacted with a protein degradation inhibitor. In embodiments, parameters include the ability to produce a product, such as a polypeptide, such as a recombinant polypeptide, such as a recombinant polypeptide expressed from an exogenous nucleic acid. In embodiments, parameters include the ability to produce a product (e.g., a polypeptide, such as a recombinant polypeptide), and wherein the increase is determined by measuring or quantifying a product (e.g., a polypeptide, such as a recombinant polypeptide) in or secreted by a cell. In embodiments, the parameter comprises cell survival, and wherein the increase or decrease is determined by measuring or quantifying the number of apoptotic cells. In embodiments, the parameter comprises culture viability, and wherein the increase or decrease is determined by measuring or quantifying the number of live cells.
[0082] In embodiments where the recombinant polypeptide is secreted from the cell, the method may include the step of recovering, collecting or isolating the recombinant polypeptide from the cell, a population of cells, or the medium in which the cells are cultured.
[0083] In certain embodiments of any of the formulations described herein, at least 70, 80, 90, 95, 98, or 99% by weight or number of the polypeptides in the formulation are properly folded or functionally active.
[0084] In certain embodiments of any of the mixtures described herein, the product, e.g., the polypeptide, e.g., the recombinant polypeptide, is present at a concentration, by weight or number, higher than that seen in cells that have not been contacted with the protein degradation inhibitor, e.g., at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more; or
[0085] wherein at least 70, 80, 90, 95, 98 or 99% by weight or number of the product, e.g., the polypeptide, e.g., the recombinant polypeptide, in the mixture is properly folded or functionally active.
[0086] In certain embodiments of any of the medium formulations described herein, the product, e.g., the polypeptide, e.g., the recombinant polypeptide, is present at a concentration higher by weight or number than that seen in cells that have not been contacted with the protein degradation inhibitor, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, or 30% higher; or
[0087] wherein at least 70, 80, 90, 95, 98 or 99% by weight or number of the product, e.g., the polypeptide, e.g., the recombinant polypeptide, in the mixture is properly folded or functionally active.
[0088] In embodiments, any of the methods described herein may further comprise steps (f), (g), or both (f) and (g):
[0089] f) culturing the cell or cell progeny in the absence of the exogenous protein degradation inhibitor (e.g., for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more generations or for at least 12, 24, 48, 72 hours);
[0090] g) evaluating the level of recombinant protein produced by the cell or the progeny of the cell, e.g., to obtain a value for the recombinant protein produced by the cell or the progeny of the cell; and
[0091] h) optionally, comparing the value obtained in g) with said reference value, wherein said reference value is the level of the recombinant protein produced by cells of the same type as the cells provided in a) cultured in the absence of an exogenous protein degradation inhibitor.
[0092] In embodiments, for example, embodiments of the methods of production herein, the method further comprises selecting a cell for a method of preparing a recombinant protein (e.g., a recombinant therapeutic protein). In embodiments, the method further comprises introducing an exogenous nucleic acid into the cell (e.g., after step c), after step d), after step e), or after step f), optionally, wherein introducing the exogenous nucleic acid comprises transfection, electroporation, or transduction.
[0093] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. Although methods and materials similar or equivalent to those described herein can be used for the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference as a whole. In addition, materials, methods and examples are only illustrative and not restrictive. Titles, subtitles or numbering or letter elements, such as (a), (b), (i), etc., are presented only for ease of reading. The use of titles or numbering or letter elements in this document does not require that steps or elements be performed in alphabetical order, or that steps or elements must be separated from each other. Other features, objects and advantages of the present invention will be apparent from the specification and drawings and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0094] Figures 1A-1C is a series of graphs showing a preliminary assessment of the effects of various concentrations of the indicated protein degradation inhibitors on growth parameters of a recombinant CHO cell line. Samples were taken at the indicated time points and cell concentration and culture viability (%) were determined on a ViCell instrument.
[0095] Figures 2A-2F is a series of graphs showing further evaluation of various concentrations of the indicated protein degradation inhibitors on growth parameters of recombinant CHO cell lines. Samples were taken at the indicated time points and cell concentration and culture viability (%) were determined on a ViCell instrument.
[0096] Figures 3A-3D Is a series of graphs showing the viable cell concentration and culture viability of a panel of cell lines producing CHO antibodies when cultured in the presence of MG132. Average viable cell concentration and culture viability after 24 and 48 hours of culture in the presence of 0.5 μM MG132 (bars with shaded) or DMSO (bars with dotted shaded). Error bars show the standard deviation of triplicate samples taken at each time point.
[0097] Figures 4A-4DIs a series of graphs showing the live culture cell concentration and culture viability of a panel of cell lines producing CHO antibodies when cultured in the presence of epoxomicin. Average live cell concentration and culture viability after culturing for 24 and 48 hours in the presence of 0.05 μM epoxomicin (shaded bars) or DMSO (dashed shaded bars). Error bars show the standard deviation of triplicate samples taken at each time point.
[0098] Figures 5A-5D is a series of graphs showing the viable cell concentration and culture viability of a panel of CHO antibody-producing cell lines when cultured in the presence of eeyarestatin I. Average viable cell concentration and culture viability after 24 and 48 hours of culture in the presence of 10 μM eeyarestatin I (shaded bars) or DMSO (dashed shaded bars). Error bars show the standard deviation of triplicate samples taken at each time point.
[0099] Figures 6A-6G is a series of graphs showing the correlation between susceptibility to proteasome and ERAD inhibitors (e.g., culture viability and / or viable cell concentration in the presence of inhibitors) and productivity data from fed-batch and bioreactor cultures of a panel of CHO cell lines producing monoclonal antibodies at a proteasome and ERAD inhibitor concentration. The data were plotted and the best fit line was identified by linear regression analysis. The relationship between the parameters was assessed using the Pearson Product Moment Correlation coefficient. Statistically significant correlations were found (p<0.05) as shown.
[0100] Figures 7A-7F is a series of gel images showing analysis of proteasome activity using activity profiling probes and fluorescence intensity. Proteasome activity was determined in a range of antibody producing cell lines using fluorescently labeled activity probes with different reactive groups. Cell lysates incubated with the probes were analyzed on 14% SDS-PAGE and fluorescence was measured on a Typhoon 9400 instrument using Cy3 and Cy2 filters. Fig. 7A and 7B Display MV151 probe, Figure 7C and 7D The MVB003 probe is shown, while Fig. 7E and 7F The MVB072 probe is shown. The right hand image ( Figure 7B , 7D and 7F ) show Coomassie blue stained images as loading control.
[0101] Figures 8A-8Fis a series of images showing analysis of proteasome activity using activity profiling probes and fluorescence intensity. Proteasome activity was determined in a range of antibody producing cell lines using fluorescently labeled activity probes with different reactive groups. Cell lysates incubated with the probes were analyzed on 14% SDS-PAGE and fluorescence was then measured on a Typhoon 9400 using Cy3 and Cy2 filters. Fig. 8A and 8B Display RUB1001 probe, Figure 8C and 8D The RUB1018 probe is shown, while Fig. 8E and 8F A no-probe control is shown. The right-hand image ( Figure 8B , 8D and 8F) show images stained with Coomassie blue as a loading control.
[0102] Figures 9A-9F is a series of graphs showing the activity of different catalytic subunits of the proteasome as determined using an activity-based profiling approach and subsequent quantification of band intensity. For those from Fig. 7A , 7C Densitometry was performed on the bands of the gels in 7E, 8A, 8C, and 8E. The graph shows the band intensity for each probe tested as well as the sum of all probes summarized in the overall proteasome map.
[0103] Fig.10 Schematic diagram depicting the protocol for constructing a cell line with the CHOK1 GS-KO cell line. A series of concentrations of methionine sulfoximide (MSX) selection was performed 24 hours after transfection of 40 μg of linearized DNA. Proteasome inhibitors were then added at a range of concentrations and combinations at 24, 96, or 168 hours after transfection following the design of the experimental plan.
[0104] Fig.11 The graph shows the growth characteristics of cell populations generated using the cell line establishment process in the presence of MSX and different proteasome inhibitor selection pressures. In addition to MSX, the culture viability and viable cell concentration of GSKO cell pools expressing a model monoclonal antibody (Antibody A) were determined every 48-72 hours after establishing the cell line with proteasome inhibitors.
[0105] Fig.12 The graph shows the antibody concentration achieved from the cell population generated using the cell line establishment process in the presence of MSX and different proteasome inhibitor selection pressures and different selection pressures. The GSKO cell line expressing Antibody A was cultured under batch culture conditions and ELISA assays were performed with proteasome inhibitors in addition to MSX selection pressure in supernatants collected after 192 hours of culture after establishment of the cell line.
[0106] Fig.13 Depicted is an experimental design for evaluating the use of exemplary proteasome inhibitors described herein during cell line construction.
[0107] Fig.14 is a bar graph depicting the average mAb product concentration achieved following the recombinant GS-CHO cell line construction process with various inhibitors in batch cultures set up from cells cultured continuously in the presence of the inhibitor. The cB72.3 mAb concentration was assessed from supernatant samples obtained at 0.2 x 10 of the cell pool generated from the cell line construction with the proteasome inhibitor in addition to the MSX selection pressure. 6 20 mL batch cultures were harvested 48, 66 and 168 hours after inoculation of 10 viable cells / ml. Product titers were assessed using a protein A sensor on the Octet system (n=3 for 37.5 μM MSX control, n=2 for inhibitor treatments except for 25 nM epoxomicin n=1).
[0108] Fig.15 Depicted is a western blot analysis of monoclonal antibody products achieved following the recombinant GS-CHO cell line construction process with various inhibitors in batch cultures set up from cells cultured continuously in the presence of inhibitors. cB72.3 concentrations were assessed from supernatant samples at 0.2 x 10 of cell pools generated from cell line construction with proteasome inhibitors in addition to MSX selection pressure. 6 The cells were harvested 168 hours after inoculation with 100 viable cells / ml. Western blots were probed with an anti-heavy chain antibody (Sigma).
[0109] Fig.16 is a bar graph depicting the average mAb product concentrations achieved following the recombinant GS-CHO cell line construction process with various inhibitors in batch cultures set up from cells cultured for two generations in the absence of inhibitors. The cB72.3 mAb concentrations were assessed from supernatant samples obtained at 0.2 x 10 of the cell pool generated from the cell line construction with proteasome inhibitors in addition to the MSX selection pressure. 6 20 mL batch cultures were harvested 48, 96 and 168 hours after inoculation of 10 viable cells / ml. Product titers were assessed using a protein A sensor on the Octet system (n=3 for 37.5 μM MSX control, n=2 for inhibitor treatments except for 25 nM epoxomicin n=1).
[0110] Fig.17Depicted are western blot analysis of monoclonal antibody products following the recombinant GS-CHO cell line construction process with various inhibitors from batch cultures set up from cells grown for two generations in the absence of inhibitors. cB72.3 concentrations were assessed from supernatant samples at 0.2 x 10 of cell pools generated from cell line construction with proteasome inhibitors in addition to MSX selection pressure. 6 Cells were harvested at 168 hours post-inoculation at 100 viable cells / ml. Cell pools were passaged twice in the absence of inhibitors before sampling batch cultures. Western blots were probed with an anti-heavy chain antibody (Sigma).
[0111] Fig.18 is a bar graph depicting the average specific productivity calculated after the cell line establishment process immediately after treatment with inhibitors. Specific productivity was calculated from data collected on viable cell number (determined on Vicell) and product concentration (derived using a protein A probe on the octet system) from supernatant samples at 0.2×10 of a cell pool generated from cell line establishment with proteasome inhibitors in addition to MSX selection pressure. 6 The viable cells / ml were harvested 48, 96 and 168 hours after inoculation. The individual specific activity of each cell pool was calculated and then the mean for each treatment was determined (n=3 for 37.5 μM MSX control, n=2 for inhibitor treatments, except for 25 nM epoxomicin n=1).
[0112] Fig.19 is a bar graph depicting the calculated average cellular monoclonal antibody specific productivity achieved after the recombinant GS-CHO cell line construction process with various inhibitors in batch cultures set up from cells cultured for two generations in the absence of inhibitors. The specific productivity was calculated from the cell number (determined on Vicell) and product concentration (derived using a protein A probe on the octet system) determined from supernatant samples at 0.2×10 of the cell pool generated from the cell line construction with proteasome inhibitors in addition to the MSX selection pressure. 6 The viable cells / ml were harvested at 48, 96 and 168 hours post-inoculation in batch culture. The individual specific activity of each cell pool was calculated and then the mean for each treatment was determined (n=3 for 37.5 μM MSX control, n=2 for inhibitor treatments, except for 25 nM epoxomicin n=1).
[0113] Fig. 20is a bar graph depicting the antibody product concentrations achieved after transient transfection in batch cultures of host cell pools after incubation in the presence of proteasome or ERAD inhibitors. 7 cB72.3 concentrations were assessed in supernatant samples collected 48, 96, and 168 hours after transfection after 10 cells were resuspended in 20 ml culture. Host cell lines were cultured in the presence of indicated proteasome and ERAD inhibitors at indicated concentrations prior to electroporation. Product titers were assessed using a protein A sensor on the Octet system.
[0114] Fig.21 is a bar graph depicting the antibody product concentration achieved after initial culture in the presence of proteasome or ERAD inhibitors, followed by subsequent subculture for 2 generations in the absence of inhibitors, followed by transient batch culture followed by transient transfection of CHO host cell pools. 7 cB72.3 concentration was assessed in supernatant samples collected 48, 96 and 168 hours after transfection after 10 cells were resuspended in 20 ml batch cultures. Host cell lines were initially cultured in the presence of proteasome and ERAD inhibitors prior to electroporation and then passaged twice in the absence of inhibitors. Product titers were assessed using a protein A sensor on the Octet system.
[0115] Fig. 22 Depicted are Western blot analyses of antibodies in supernatants of batch cultures following transient transfection of host cell pools immediately after culture in the presence of proteasome or ERAD inhibitors (left gel) or after two passages of subculture in the absence of inhibitors (right gel). 7 cB72.3 concentration was assessed in supernatant samples taken 168 hours after transfection after 10 cells were grown and resuspended in 20 ml batch cultures. Host cell lines were initially cultured in the presence of proteasome and ERAD inhibitors prior to electroporation and then passaged twice in the absence of inhibitors. Western blots were probed with an anti-heavy chain antibody (Sigma).
[0116] Fig.23is a bar graph depicting the estimated cell specific productivity determined from supernatant samples collected during routine culture of recombinant cell pools generated at different passage numbers using protein degradation inhibitors. cB72.3 concentrations were assessed from supernatant samples collected every 3-4 days during routine subculture after successful resuscitation of pools from cell line construction with the addition of proteasome inhibitors. Product titers were assessed using a protein A sensor on the Octet system, and product levels per cell were then determined using cell counts determined on the ViCell. DETAILED DESCRIPTION
[0117] Recombinant protein or polypeptide can be produced by recombinant DNA technology, expressed by host cells, and can be purified or secreted from host cells (e.g., Escherichia coli) into the fluid of culturing host cells, such as cell culture medium, and purified from fluid. It is highly desirable in the art to produce cells of recombinant protein or polypeptide with high yield and appropriate quality. The method disclosed herein for evaluating, classifying, identifying, generating or selecting cells for producing recombinant polypeptides can be used to identify or generate high-productivity cells, obtain the high yield of recombinant polypeptide products or provide higher-quality recombinant polypeptide product preparations. The method disclosed herein is particularly useful for the production of recombinant therapeutic polypeptides, wherein effective cell line development, a large amount of recombinant therapeutic polypeptide products, and high-quality grades for therapeutic use of patients are required.
[0118] definition
[0119] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice and / or testing of the present invention, preferred materials and methods are described herein. In describing and claiming the present invention, the following definitions should be used according to how they are defined and where the definitions are provided.
[0120] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
[0121] The articles "a" and "an" are used herein to refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "a cell" can refer to one cell or to more than one cell.
[0122] As used interchangeably herein, the term "protein degradation inhibitor" or "protein degradation pathway inhibitor" refers to an agent, such as a compound, that reduces (e.g., slows, attenuates, alters) protein degradation, such as a partial or complete reduction of a protein to its polypeptide, peptide or amino acid components during protein synthesis and cellular secretion. For example, a protein degradation inhibitor can be identified by preventing or reducing (e.g., slowing, attenuating or altering) the ability to: identify proteins for degradation; mark proteins for degradation; retrotranslocation of proteins from the ER to the cytosol; binding of proteins to proteasomes or binding of proteasomes to proteins; protein entry into the proteasome; protein unfolding to enter the proteasome; proteasome processing of proteins; release of processed peptides from the proteasome; binding of the proteasome to the endoplasmic reticulum; and / or the proteasome capacity of the cell; for example, in a cell treated with a candidate inhibitor compared to a similar cell not treated with the candidate inhibitor. In another embodiment, a protein degradation inhibitor causes a condition in the cell that prevents or reduces proteasome activity, such as in a cell treated with a candidate inhibitor, compared to a similar cell not treated with the candidate inhibitor. In another embodiment, the protein degradation inhibitor saturates the proteasome activity of the cell, for example, in cells treated with the candidate inhibitor, compared to similar cells not treated with the candidate inhibitor. The proteasome degradation of proteins, such as endogenous or exogenously expressed proteins, can be measured or quantified by heavy / light isotope pulse labeling methods, such as stable isotope labeling (SILAC) with amino acids in cell culture followed by mass spectrometry (MS). Other methods that can be used to assess protein degradation are further described in Alvarez-Castelao et al., Biochemistry Research International, Volume 2012 (2012), Article ID 823597, page 11 (which is incorporated herein by reference).
[0123] As used herein, the term "protein degradation pathway" refers to a cellular process that causes a protein to be partially or completely reduced to its polypeptide, peptide or amino acid components, such as the degradation of misfolded, excess, truncated or non-functional proteins. Exemplary elements of protein degradation pathways include, but are not limited to, proteasomes (e.g., 26S proteasomes or components thereof, such as 20S core or catalytic subunits, 19S regulatory subunits or 11S regulatory subunits), enzymes that promote the identification of proteins to be degraded or ubiquitinated (e.g., E1 ubiquitin activating enzymes, E2 ubiquitin conjugating enzymes or E3 ubiquitin ligases); or enzymes that promote protein translocation or reverse translocation from the ER to another element of the protein degradation pathway, such as the cytosol or proteasome (e.g., reverse translocation enzyme / complex).
[0124] As used herein, the term "proteasome inhibitor" refers to a molecule that prevents or reduces the activity of a proteasome or a proteasome component. In one embodiment, the proteasome comprises a 20S catalytic or proteolytic core subunit, and one or more regulatory subunits, such as one or more 19S regulatory particles and / or one or more 11S regulatory particles. In an embodiment, the activity of a proteasome or a proteasome component includes one or more of the following: binding of a protein to a proteasome or binding of a proteasome to a protein; protein entry into a proteasome; protein unfolding to enter a proteasome; processing of a protein by a proteasome (e.g., partial or complete reduction of a protein to a peptide or amino acid component); release of a processed peptide or amino acid derived from protein processing from a proteasome; and binding of a proteasome to the endoplasmic reticulum. In one embodiment, a proteasome inhibitor reduces the activity of a proteasome or a proteasome component by about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% compared to the activity of the proteasome or a component thereof in the absence of the inhibitor.
[0125] As used herein, the term "ubiquitin pathway inhibitor" refers to a molecule that prevents or reduces the activity of one or more components of the ubiquitin pathway. The ubiquitin pathway is a process of identifying a target protein to be degraded and marking it with a ubiquitin molecule for proteasome recognition and degradation. The components of the ubiquitin pathway include ubiquitin activating enzymes (E1), ubiquitin conjugating enzymes (E2), and ubiquitin ligases (E3). In embodiments, the activity of one or more components of the ubiquitin pathway includes one or more of the following: identifying proteins for degradation, such as by E3 ubiquitin ligases or substrate identification complexes; activating ubiquitin, such as by E1 activating enzymes; transferring ubiquitin from E1 to E2 enzymes; and conjugating ubiquitin to ubiquitin molecules or chains (e.g., extending ubiquitin chains) on proteins or proteins, such as by E3 ubiquitin ligases; deubiquitination by deubiquitinating enzymes. In one embodiment, the ubiquitin pathway inhibitor reduces the activity of one or more components of the ubiquitin pathway by about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 95%, or 99% or more compared to the activity of the one or more components of the ubiquitin pathway in the absence of the ubiquitin pathway inhibitor.
[0126] As used herein, the term "ERAD inhibitor" refers to a molecule that prevents or reduces the activity of one or more components of the endoplasmic reticulum-associated degradation (ERAD) pathway. The ERAD pathway targets misfolded, mutated or non-functional proteins of the endoplasmic reticulum for ubiquitination and subsequent degradation by the proteasome. The components of the ERAD pathway include chaperones, such as Hsp70 family members, Hsp40 family members, Hsp90 family members, nucleotide exchange factors, small heat shock proteins, lectin-like chaperones; enzymes that identify or mark misfolded proteins, such as α-mannosidase; enzymes or protein complexes that assist the reverse translocation of misfolded proteins, such as reverse translocation complexes (RTC); enzymes or protein complexes of ubiquitinated reverse translocation proteins, such as Hrd-Der ubiquitin ligase complexes; and enzymes or protein complexes that deliver ubiquitinated proteins to the proteasome, such as Cdc48-Ufd1-Np14 complexes. In embodiments, the activity of one or more components of the ERAD pathway includes one or more of the following: identification or marking of misfolded non-functional proteins for degradation; reverse translocation of proteins from the ER to the cytosol; ubiquitination of proteins at the ER membrane, for example, integrated into the ER membrane; delivery of ubiquitinated proteins to the proteasome; or deubiquitination of proteins. In one embodiment, the ERAD inhibitor reduces the activity of one or more components of the ERAD pathway by about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more compared to the activity of one or more components of the ERAD pathway in the absence of an ERAD inhibitor.
[0127] As used herein, the expression "low concentration" when used in conjunction with a protein degradation inhibitor, such as "low concentration of a proteasome inhibitor," "low concentration of an ubiquitination pathway inhibitor," or "low concentration of an ERAD inhibitor," refers to a concentration of a protein degradation inhibitor that results in a decrease in culture viability, such as a 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% decrease when treated with a protein degradation inhibitor compared to a culture that has not been treated with the protein degradation inhibitor. Since the purpose of using a protein degradation inhibitor is to identify or select cells with improved productivity or improved production quality, a low concentration of a protein degradation inhibitor is a concentration that is less than the concentration used to kill diseased cells, such as cancer cells, for therapeutic benefit. It should be understood that a culture viability of less than 30%, such as 20%, 10%, 5%, 1%, 0.5%, 0.1%, can still result in a population of selected cells with improved productivity and producing a better quality product, and is also within the scope of the present disclosure. In another embodiment, a low concentration of a protein degradation inhibitor is a concentration that partially but not completely inhibits protein degradation, such as a protein or process associated with protein degradation. For example, a low concentration of a proteasome inhibitor is a concentration that partially but not completely inhibits protein degradation. Methods of measuring proteasome activity (e.g., inhibiting proteasome activity) are described herein.
[0128] As used herein, the term "endogenous" refers to any material that originates from or occurs naturally within an organism, cell, tissue or system.
[0129] As used herein, the term "exogenous" refers to any material that is introduced into an organism, cell, tissue, or system or produced outside an organism, cell, tissue, or system. Therefore, "exogenous nucleic acid" refers to a nucleic acid that is introduced into an organism, cell, tissue, or system or produced outside an organism, cell, tissue, or system. In one embodiment, the sequence of the exogenous nucleic acid is not naturally produced inside the organism, cell, tissue, or system into which the exogenous nucleic acid is introduced, or is not naturally found inside the organism, cell, tissue, or system into which the exogenous nucleic acid is introduced. In one embodiment, the sequence of the exogenous nucleic acid is a non-naturally occurring sequence, or encodes a non-naturally occurring product.
[0130] As used herein, the term "heterologous" refers to any material from one species when introduced into an organism, cell, tissue or system from a different species.
[0131] As used herein, the terms "nucleic acid", "polynucleotide" or "nucleic acid molecule" are used interchangeably and refer to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in single-stranded or double-stranded form, or a combination of its DNA or RNA, and polymers thereof. The term "nucleic acid" includes, but is not limited to, genes, cDNAs or mRNAs. In one embodiment, nucleic acid molecules are synthetic (e.g., chemically synthesized or artificial) or recombinant. Unless otherwise specified, the term includes molecules containing analogs or derivatives of natural nucleotides that have similar binding properties to reference nucleic acids and are metabolized in a manner similar to natural or non-naturally occurring nucleotides. Unless otherwise indicated, a specific nucleic acid sequence also implicitly includes variants (e.g., degenerate codon substitutions), alleles, orthologs, SNPs and complementary sequences thereof, as well as sequences explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0132] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to compounds consisting of amino acid residues covalently linked by peptide bonds or by means other than peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that can comprise a protein or peptide sequence. In one embodiment, a protein may contain more than one, for example, two, three, four, five or more polypeptides, each of which is bound to another polypeptide by a covalent or non-covalent bond / interaction. Polypeptides include any peptide or protein that contains two or more amino acids linked to each other by means other than peptide bonds or by means other than peptide bonds. As used herein, the term refers to both short chains (which are also commonly referred to in the art as, for example, peptides, oligopeptides and oligomers) and longer chains (which are generally referred to in the art as proteins, of which there are many types). "Polypeptides" include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, etc.
[0133] As used herein, "product" refers to a product produced by a cell that has been modified or engineered to produce a product, such as an expressed molecule, nucleic acid, polypeptide, or any hybrid thereof. In one embodiment, the product is a naturally occurring product or a non-naturally occurring product, such as a synthetic product. In one embodiment, a portion of the product is naturally occurring, while another portion of the product is non-naturally occurring. In one embodiment, the product is a polypeptide, such as a recombinant polypeptide. In one embodiment, the product is suitable for diagnosis or preclinical use. In another embodiment, the product is suitable for therapeutic use, such as for the treatment of a disease. In one embodiment, the product is selected from Table 1 or Table 2. In one embodiment, the modified or engineered cell comprises an exogenous nucleic acid that controls expression or encodes the product. In other embodiments, the modified or engineered cell comprises other molecules that control the expression or construction of the product in the cell, such as other molecules that are not nucleic acids.
[0134] In one embodiment, the modification of the cell comprises the introduction of an exogenous nucleic acid comprising a nucleic acid sequence that controls or alters (e.g., increases) the expression of an endogenous nucleic acid sequence (e.g., an endogenous gene). In such embodiments, the modified cell produces an endogenous polypeptide product that is naturally or endogenously expressed by the cell, but the modification increases the production of the product and / or the quality of the product compared to an unmodified cell, e.g., compared to the endogenous production or quality of the polypeptide.
[0135] In another embodiment, the modification of the cell comprises the introduction of an exogenous nucleic acid encoding a recombinant polypeptide as described herein. In such embodiments, the modified cell produces a recombinant polypeptide product that may be naturally occurring or non-naturally occurring. In such embodiments, the modified cell produces a recombinant polypeptide product that may also be endogenously expressed by the cell or not endogenously expressed by the cell. In embodiments where the recombinant polypeptide product is also endogenously expressed by the cell, the modification increases the production and / or quality of the product compared to the unmodified cell, for example, compared to the endogenous production or quality of the polypeptide.
[0136] As used herein, "recombinant polypeptide" or "recombinant protein" refers to a polypeptide that can be produced by a cell as described herein. A recombinant polypeptide is a polypeptide formed by genetic engineering (of a cell or precursor cell) of at least one nucleotide of a sequence encoding a polypeptide or a sequence controlling the expression of a polypeptide; for example, at least one nucleotide is changed, for example, introduced into a cell or it is the product of genetic engineering rearrangement. In one embodiment, the sequence of the recombinant polypeptide is not different from the naturally occurring isoform of the polypeptide or protein. In one embodiment, the amino acid sequence of the recombinant polypeptide is different from the sequence of the naturally occurring isoform of the polypeptide or protein. In one embodiment, the recombinant polypeptide and the cell are from the same species. In one embodiment, the recombinant polypeptide is endogenous to the cell, in other words, the cell is from a first species, and the recombinant polypeptide is native to the first species. In one embodiment, the amino acid sequence of the recombinant polypeptide is identical or substantially identical to the polypeptide encoded by the endogenous genome of the cell, or differs by no more than 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%. In one embodiment, the recombinant polypeptide and the cell are from different species, for example, the recombinant polypeptide is a human polypeptide, and the cell is a non-human cell, such as a rodent cell, such as CHO, or an insect cell. In one embodiment, the recombinant polypeptide is foreign to the cell, in other words, the cell is from a first species, and the recombinant polypeptide is from a second species. In one embodiment, the polypeptide is a synthetic polypeptide. In one embodiment, the polypeptide is derived from a non-naturally occurring source. In one embodiment, the recombinant polypeptide is a human polypeptide or protein that is not different in amino acid sequence from a naturally occurring isoform of a human polypeptide or protein. In one embodiment, the recombinant polypeptide differs from a naturally occurring isoform of a human polypeptide or protein at no more than 1, 2, 3, 4, 5, 10, 15, or 20 amino acid residues. In one embodiment, the recombinant polypeptide differs from a naturally occurring isoform of a human polypeptide at no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 15% of its amino acid residues.
[0137] The disclosure of each patent, patent application and publication cited herein is incorporated herein by reference in its entirety. Although the present invention has been disclosed with reference to specific aspects, it is apparent that other aspects and variations of the present invention may be devised by those skilled in the art without departing from the true spirit and scope of the present invention. The appended claims are intended to be interpreted as including all these aspects and equivalent variations.
[0138] Regulates protein degradation pathways
[0139] During cell line construction, such as recombinant cell line construction, cellular processes are triggered within the cell when the folding and modification capacity of the cell is exceeded. The unfolded protein response (UPR) and ER-associated degradation (ERAD) during ER stress are key cellular processes for handling misfolded or unassembled proteins during protein synthesis. Key responses activated by these processes include upregulation of ER chaperones, reduction of global protein synthesis by reducing translation initiation, and ultimately (if stress persists) apoptosis (Schroder and Kaufman 2005; Chakrabarti et al. 2011). It is proposed that 30% of newly translated polypeptides are targeted for degradation, possibly as a result of misfolding (Du et al. 2013; Schubert et al. 2000; Yewdell and Nicchitta 2006). It is believed that these processes not only help maintain protein quality, but also provide an important source of "recycled" amino acids as new building blocks for the synthesis of new polypeptides. Therefore, it is important that cells have appropriate mechanisms to handle and recycle components of misfolded polypeptides and maintain quality control processes.
[0140] ERAD requires that polypeptides / proteins in the ER destined for destruction are transported from the ER back to the cytosol, such as reverse translocation, where they are degraded by the proteasome (Olzmann et al., 2013). If homeostasis cannot be restored, the process of UPR activation can eventually lead to apoptosis. The UPR provides cells with the ability to regulate ER capacity during high demand periods, and it is believed that the elements of UPR induction are beneficial to recombinant protein yields, but excessive and long-term activation can be harmful to cell and culture viability.
[0141] The present disclosure is based in part on the results of studies to determine whether the ability of a cell to initiate protein turnover from the ER correlates with the ability of the cell to produce a recombinant polypeptide, and further, whether inhibition of protein degradation pathways (e.g., by inhibiting proteasome activity during ERAD or polypeptide transport out of the ER) can be used to select cells with enhanced abilities for these processes, which in turn will reflect their ability to produce recombinant proteins. The present disclosure provides methods and compositions for identifying or selecting cells with the ability to produce a high yield of a product, such as a recombinant polypeptide, using a protein degradation inhibitor, and for generating recombinant cell lines with increased yields, such as those that produce a higher yield of a recombinant polypeptide product, and / or that can produce a higher quality recombinant polypeptide product.
[0142] Protein degradation inhibitors
[0143] Methods described herein include contacting a cell or cell colony with a protein degradation inhibitor. In one embodiment, the protein degradation inhibitor described herein inhibits or reduces the activity of a process or protein involved in a protein degradation pathway, such as proteasome degradation, ER-related degradation pathways and / or ubiquitin pathways. As described herein, protein degradation inhibitors may include but are not limited to proteasome inhibitors, ubiquitin pathway inhibitors or ERAD inhibitors. In one embodiment, the inhibitor may be reversible or irreversible. In embodiments, the inhibitor may be a small molecule, a nucleic acid or a polypeptide.
[0144] The proteasome is a large multi-enzyme complex that includes one or more protein digesting enzymes, such as proteases. The 26S proteasome includes a 20S proteolytic core subunit and one or two 19S regulatory particles. The 20S core includes three types of active sites, such as proteolytic or peptidase sites. In an embodiment, the proteasome inhibitors described herein can inhibit or reduce the activity of any component of the proteasome. In one embodiment, the proteasome inhibitor binds and / or inhibits one or more active sites of the proteasome component, such as one or more active sites of the 20S proteolytic core. In one embodiment, the proteasome inhibitor inhibits or reduces the activity of the 20S proteolytic core. In one embodiment, the proteasome inhibitor inhibits or reduces the activity of the 19S regulatory particles. In some embodiments, the proteasome inhibitor inhibits or reduces the activity of proteases, such as trypsin protease, chymotrypsin protease or calpain (calpain). In one embodiment, a proteasome inhibitor reduces the activity of a proteasome or a proteasome component by about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% compared to the activity of the proteasome or a component thereof in the absence of the inhibitor.
[0145] In one embodiment, the proteasome inhibitor is selected from MG132 or epoxomicin. Other exemplary proteasome inhibitors are known in the art, including but not limited to Z-Leu-Leu-Leu-B(OH)2 (MG262), bortezomib (PS-341, Velcade, pyrazinecarbonyl-Phe-Leu-borate), carfilzomib (PR-171), marizomib, MLN9708 (Ninlaro), ixazomib (MLN2238), oprozomib (ONX 0912), delanzomib (CEP-18770), CEP1612, celastrol, ONX-0914 (PR-957), disulfiram, epigallocatchin-3-gallate, salinosporamide A, AM114, lactacystin, ps-341, eponomicin, Z-Leu-Leu-LeuVS, MG115, calpeptin, PSI, and calpain inhibitor II. Other exemplary proteasome inhibitors include NVLS, PS-519, antiprotealide, fluorosalinosporamide, and cinnabaramides (e.g., Cinnabaramides AG).
[0146] The proteasome inhibitor can be any of those described in Dick et al., Biochem. 30:2725 (1991); Goldberg et al., Nature 357:375 (1992); Goldberg, Eur. Biochem. 203:9 (1992); Orlowski, Biochem. 29:10289 (1989); Rivett et al., Archs. Biochem. Biophys. 218:1 (1989); Rivett et al., J. Biol. Chem. 264:12, 215 (1989); Tanaka et al., New Biol. 4:1 (1992), and U.S. Pat. No. 5,693,617.
[0147] The proteasome inhibitor may be a peptide aldehyde or a peptide α-ketoester containing a hydrophobic residue in the P1 position, as described in Vinitsky et al. (Biochem. 31: 9421 (1992), see also Orlowski et al., Biochem. 32: 1563 (1993)), which is characterized as an inhibitor of the chymotrypsin-like activity of the proteasome. The proteasome inhibitor may be a tripeptide, such as Ac-Leu-Leu-Leu-H, Ac-Leu-Leu-Met-OR, Ac-Leu-Leu-Nle-OR, Ac-Leu-Leu-Leu-OR, Ac-Leu-Leu-Arg-H, Z-Leu-Leu-Leu-H, Z-Arg-Leu-Phe-H, and Z-Arg-Ile-Phe-H, wherein OR together with the carbonyl group of the preceding amino acid residue represents an ester group.
[0148] As disclosed by Siman et al. (WO 01 / 13904), proteasome inhibitors may be inhibitors of chymotrypsin-like proteases. These inhibitors have the formula R-A4-A3-A2-Y, wherein R is hydrogen, or an N-terminal blocking group; A4 is a covalent bond, an amino acid or a peptide; A3 is a covalent bond, a D-amino acid, Phe, Tyr, Val or a conservative amino acid substitution of Val; A2 is a hydrophobic amino acid or lysine or a conservative amino acid substitution thereof, or when A4 comprises at least two amino acids, A2 is any amino acid; and Y is a group reactive with the active site of the protease. Proteasome inhibitors may also be peptide ketoamides, ketoacids or ketoesters useful for inhibiting serine and cysteine proteases, as described in Powers (WO 92 / 12140). Proteasome inhibitors may also be calpain inhibitor compounds as described by Bartus et al. (WO 92 / 1850).
[0149] Other proteasome inhibitors include, but are not limited to, calpain inhibitor I, MG101, calpain inhibitor II, fraction I (FrI, Hela), fraction II (FII), clasto-lactacystin β-lactone, beta-lactone)(omuralide), Lactacystin, MG-115, antiserum against NEDD8, PA28 activator, 20S proteasome, polyclonal antibody against proteasome 20S α-1 type subunit, polyclonal antibody against proteasome 26S subunit S10B, polyclonal antibody against proteasome 26S subunit S2, polyclonal antibody against proteasome 26S subunit S4, polyclonal antibody against proteasome 26S subunit S5A, polyclonal antibody against proteasome 26S subunit S6, polyclonal antibody against proteasome 26S subunit S6', polyclonal antibody against proteasome 26S subunit S7, polyclonal antibody against proteasome 26S subunit S8, polyclonal antibody against proteasome activator PA28α, polyclonal antibody against proteasome activator PA28γ, polyclonal antibody against proteasome activator PA700 subunit 10B , 26S proteasome fraction, proteasome inhibitor I, proteasome inhibitor II, proteasome substrate I (fluorescent), proteasome substrate II (fluorescent), proteasome substrate III (fluorescent), proteasome substrate IV (fluorescent), S-100 fraction, SUMO-1 / Sentrin-1 (1-101), SUMO-1 / Sentrin-1 (1-97), antiserum against SUMO-1 / Sentrin-1, U bc10, Ubc5b, Ubc5c, Ubc6, Ubc7, antiserum against Ubc9, Ubc9, UbCH2 / E2-14K, UbCH3 / Cdc34, UbCH5a, ubiquitin activating enzyme (E1), ubiquitin activating enzyme (E1), ubiquitin aldehyde, ubiquitin conjugating enzyme fraction, ubiquitin C-terminal hydrolase, ubiquitin K48R, methylated ubiquitin, GST-ubiquitin, (His)6ubiquitin, ubiquitin-AMC, ubiquitin-Sepharose.
[0150] In addition to known proteasome inhibitors, proteasome inhibitors that can be used in the methods described herein can be routinely tested for their ability to inhibit proteasome activity. Various strategies for identifying such inhibitors are exemplified in the art. For example, a small molecule library that typically contains extracts from plants or simpler organisms can be screened for its ability to inhibit proteasomes or specific protease types. Alternatively, a rational design approach can be applied using, for example, peptides or peptidomimetic compounds specifically designed to interact with the active sites of proteasome components (see, for example, Siman et al., WO91 / 13904; Powers et al., in Proteinase Inhibitors, Barrett et al. (eds.), Elsevier, pp. 55-152 (1986)). The inhibitor can be a stable analog of the catalytic transition state, such as Z-Gly-Gly-Leu-H, which inhibits the chymotrypsin-like activity of the proteasome (Orlowski, Biochemistry 29: 10289 (1990); also see Kennedy and Schultz, Biochem. 18: 349 (1979)).
[0151] In addition, a variety of natural and chemical proteasome inhibitors or their analogs reported in the literature are intended to be included in the present invention, including but not limited to peptides containing α-diketones or α-ketoesters, peptide chloromethyl ketones, peptide epoxyketones, peptide vinyl sulfones, β-lactone-containing compounds, peptide boronate isocoumarins, peptide sulfonyl fluorides, peptide boronate esters, peptide epoxides, and peptide diazomethanes. Angelastro et al., J. Med. Chem. 33: 11 (1990); Bey et al., EPO 363, 284; Bey et al., EPO 363, 284; Bey et al., EPO 364, 344; Grubb et al., WO 88 / 10266; Higuchi et al., EPO 393,457; Ewoldt et al., Mol. Immunol. 29(6):713 (1992); Hernandez et al., J. Med. Chem. 35(6):1121 (1992); Vlasak et al., J. Virol. 63(5):2056 (1989); Hudig et al., J. Immunol. 147(4):1360 (1991); Odakc et al., Biochem. 30(8):2217 (1991); Vijayalakshmi et al., Biochem. 30(8):2175 (1991); Kam et al., Thrombosis and Haemostasis 64(1):133 (1990); Powers et al., J. Cell. Biochem. 39(1):33 (1989); Powers et al., Proteinase Inhibitors, Barrett et al., Eds., Elsevier, pp.55-152 (1986); Powers et al., Biochem 29(12):3108 (1990); Oweida et al., Thrombosis Res.58(2):391(1990); Hudig et al., Mol.Immunol.26(8):793(1989); Orlowski et al., Arch.Biochem.andBiophys.269(1):125(1989); Zunino et al., Biochem.et Biophys.Acta 967(3):331(1988); Kam et al., Biochem. 27(7):2547(1988); Parkes et al., Biochem. J. 230:509(1985); Green et al., J. Biol. Chem. 256:1923(1981); Angliker et al., Biochem. J. 241:871(1987); Puri et al., Arch. Biochem. Biophys.27:346 (1989); Hanada et al., Proteinase Inhibitors: Medical and Biological Aspects, Katunuma et al., ed., Springer-Verlag pp.25-36 (1983); Kajiwara et al., Biochem. Int. 15:935 (1987); Rao et al., Thromb. Res. 47:635 (1987); Tsujinaka et al., Biochem. Biophys. Res. Commun. 153:1201 (1988)).
[0152] Proteasome activity can be measured by proteasome activity assays known in the art and as described herein, for example, as described in Examples 1 and 4.
[0153] Ubiquitination plays a key role in protein degradation. Ubiquitin is a small 8.5 kDa protein that is attached to substrate proteins via an isopeptide bond between the carboxylic acid group of the ubiquitin glycine and the epsilon amino group of the lysine in the substrate protein. Ubiquitination of substrate proteins occurs in three main steps: 1) activation of ubiquitin by the ATP-dependent E1 ubiquitin activating enzyme (also referred to herein as E1); 2) transfer of ubiquitin from E2 to the active site of the E2 ubiquitin conjugating enzyme (also referred to herein as E2); 3) attachment of ubiquitin to the substrate protein by the E3 ubiquitin ligase (also referred to herein as E3), for example, formation of an isopeptide bond between the ubiquitin molecule and the substrate protein. Ubiquitinated proteins are targeted for degradation by the proteasome. In one embodiment, the ubiquitin pathway inhibitor reduces the activity of one or more components of the ubiquitin pathway by about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more compared to the activity of the one or more components of the ubiquitin pathway in the absence of the ubiquitin pathway inhibitor.
[0154] In one embodiment, the ubiquitin pathway inhibitors described herein can inhibit any step or enzyme involved in the ubiquitination cascade. For example, the ubiquitination inhibitor can inhibit or reduce the activity of one or more, such as one, two or all, of E1, E2 or E3. In one embodiment, the ubiquitin pathway inhibitor inhibits or reduces the activity of any E1, E2 or E3 known in the art. For example, E3 ubiquitin ligases include but are not limited to APC / C ubiquitin ligases, HECT E3 ubiquitin ligases, β-TrCP1 ligases, MDM2 and SCF ubiquitin ligases.
[0155] In one embodiment, the ubiquitin pathway inhibitor is (-)-parthenolide, thalidomide, TAME, A01 (Tocris, catalog number 5397), Apcin (R&D Systems, catalog number I-444), GS143 (Tocris, catalog number 5636), Heclin (Tocris, catalog number 5433), HLI373 (Tocris, catalog number 3503), NSC 66811 (Tocris, catalog number 2936), NSC-687852 (Biovision, catalog number 2021-5), NAB 2 (R&D Systems, catalog number 5131), Nutlin-3 (Tocris, catalog number 3984), PRT 4165 (Tocris, catalog number 5047), PTC 209 (Tocris, Catalog No. 5191), RITA (Tocris, Catalog No. 2443), SKPin C1 (Tocris, Catalog No. 4817), SMER3 (Tocris, Catalog No. 437), SP141 (Tocris, Catalog No. 5332), SZL P1-31 (Tocris, Catalog No. 5076), TAME HCl (Tocris, Catalog No. 4506), proTAME (R&D Systems, Cat. No. I-440), or TCID (Biovision, Cat. No. 2204-5).
[0156] Ubiquitination can be measured by ubiquitination assays known in the art.
[0157] Elimination of misfolded proteins from the ER by ER-associated degradation involves, for example, identification and marking of misfolded proteins to be degraded, reverse translocation of misfolded proteins from the ER lumen into the cytosol, protein ubiquitination, and delivery to the proteasome for degradation. The protein complex, the p97-Ufd1-Npl4 ATPase complex hydrolyzes ATP to translocate ubiquitinated proteins into the cytosol. The p97-associated deubiquitinase prevents components of the p97-Ufd1-Np14βATPase complex itself from being targeted by the proteasome, e.g., ubiquitinated and degraded. Therefore, in one embodiment, an ERAD inhibitor inhibits or reduces the activity of one or more components of the p97-Ufd1-Np14 ATPase complex, e.g., inhibits or reduces the ATPase activity of the p97-Ufd1-Np14 ATPase complex. In one embodiment, an ERAD inhibitor reduces the activity of one or more components of the ERAD pathway by about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more compared to the activity of the one or more components of the ERAD pathway in the absence of the ERAD inhibitor.
[0158] In one embodiment, the ERAD inhibitor inhibits or reduces the activity of one or more components of the ERAD pathway. Components of the ERAD pathway include, but are not limited to, Hsp70 family members, Hsp40 family members, Hsp90 family members, nucleotide exchange factors (NEFs) (e.g., Nhs, Bag-1), Rot1, calnexin, calnexin, alpha-mannosidase (Mns1), ER degradation enhancing alpha-mannosidase-like protein (EDEM), Kar2, Sec61 complex (components include, for example, Sec61α and Sec61γ), protein disulfide isomerase (PDI), Yos9, Cdc48p, p97, VCP / p97 complex, Hrd1, Doa10, Ubc1, Cue1, Ubc6, and Ubc7.
[0159] In one embodiment, ERAD inhibitors include but are not limited to eeyarestatin I (also known as ESI), cotransin, CAM741, apratoxin A, exotoxin A, HUN-7293, decatransin, valinomycin, mycolactone, NSC 630668-R / 1 (also known as R / 1), MAL3-39, MAL3-101, E6 berbamine, Ophiobolin A, CADA cyclotriazadisulfoniamide, such as those described in Kalies et al., 2015, Traffic, 16: 1027-1038, which is incorporated herein by reference.
[0160] In one embodiment, one or more protein degradation inhibitors as described herein are used in the methods herein. For example, two, three, four or five or more protein degradation inhibitors as described herein are used. In one embodiment, two or more protein degradation inhibitors can destroy the same process in the protein degradation pathway, for example, two or more inhibitors inhibit or reduce proteasome activity. In an alternative embodiment, two or more protein degradation inhibitors destroy different processes in the protein degradation pathway, for example, one inhibitor inhibits or reduces proteasome activity, and another inhibitor inhibits or reduces ERAD activity or ubiquitin pathway.
[0161] Determining the appropriate concentration of a protein degradation inhibitor is well within the skill of the skilled artisan. Assays for determining the concentration of such inhibitors, e.g., determining the appropriate concentration of an inhibitor to obtain the desired culture viability and / or protein degradation inhibition, e.g., proteasome inhibition, are described herein and in the Examples herein. The appropriate concentration of a protein degradation inhibitor for use in the methods described herein may be different in different cell types or cells from different species. In the embodiments described herein, inhibition or reduction of proteasome activity is determined compared to cells that have not been contacted with a proteasome inhibitor, or compared to reference cells that have been contacted with a proteasome inhibitor.
[0162] In some embodiments, low concentrations of protein degradation inhibitors are used in the methods described herein. Low concentrations of protein degradation inhibitors may be preferred for cells that have undergone one or more selection steps prior to contact, e.g., exposure to, a protein degradation inhibitor as described herein. For example, low concentrations of protein degradation inhibitors are applied to cells after selection to identify cells that have stably integrated exogenous nucleic acids into the genome.
[0163] In one embodiment, the concentration of the protein degradation inhibitor is one that results in inhibition or reduction of protein degradation, such as inhibition or reduction of the activity of one or more components of the proteasome, the ubiquitin pathway, or the ERAD pathway as described herein. In one embodiment, the concentration of the protein degradation inhibitor is a concentration that results in about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more culture viability in a culture or cell population contacted by, e.g., cultured in the presence of, the protein degradation inhibitor (e.g., 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more of the cells in a cell population contacted by, e.g., cultured in the presence of, the protein degradation inhibitor are viable or alive). In one embodiment, the concentration of the protein degradation inhibitor is a concentration at which a portion of the cells contacted by the protein degradation inhibitor continue to proliferate, e.g., 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more of the cells continue to proliferate when contacted by the protein degradation inhibitor and cultured in the presence of the protein degradation inhibitor. In some embodiments, the concentration of the protein degradation inhibitor described herein results in less than 20% of the total number of cells remaining after contacting the cells with the protein degradation inhibitor, e.g., culturing the cells in the presence of the protein degradation inhibitor, e.g., 15%, 10%, 5%, 1%, 0.5%, or 0.1%.
[0164] In one embodiment, the protein degradation inhibitor is MG-132. MG-132 has been used at 1.5 μM to induce apoptosis (Meriin et al., 1998). In one embodiment, the concentration of MG-132 suitable for the methods described herein is less than 1.5 μM, less than 1.25 μM, less than 1.0 μM, less than 0.9 μM, less than 0.8 μM, less than 0.7 μM, less than 0.6 μM, less than 0.5 μM, less than 0.4 μM, less than 0.3 μM, less than 0.2 μM, less than 0.1 μM, less than 0.09 μM, less than 0.08 μM, less than 0.07 μM, less than 0.06 μM, less than 0.05 μM, less than 0.04 μM, less than 0.03 μM, less than 0.02 μM, less than 0.01 μM, or less than 0.005 μM. In one embodiment, the concentration of MG-132 is about 0.1 μM or 0.0625 μM.
[0165] In one embodiment, the protein degradation inhibitor is epoxomicin. Epoxomicin concentrations of 0.04-0.08 μM have been shown to inhibit the chymotrypsin activity of the proteasome (Meng et al., 1999). In one embodiment, the concentration of epoxomicin suitable for use in the methods described herein is less than 0.08 μM, less than 0.07 μM, less than 0.06 μM, less than 0.05 μM, less than 0.04 μM, less than 0.03 μM, less than 0.02 μM, less than 0.01 μM, less than 0.009 μM, less than 0.008 μM, less than 0.007 μM, less than 0.006 μM, less than 0.005 μM, less than 0.004 μM, less than 0.003 μM, less than 0.002 μM, less than 0.001 μM, less than 0.009 μM, less than 0.008 μM, less than 0.007 μM, less than 0.006 μM, less than 0.005 μM, less than 0.004 μM, less than 0.003 μM, less than 0.002 μM, or less than 0.001 μM. In one embodiment, the concentration of epoxomicin is about 0.05 μM or 0.025 μM.
[0166] In one embodiment, the protein degradation inhibitor is eeyarestatin I. It has been previously shown in vivo that a concentration of 8 μM eeyarestatin I is sufficient to block ER translocation (Cross et al. 2009). In one embodiment, the concentration of eeyarestatin I suitable for use in the methods described herein is less than 20 μM, less than 15 μM, less than 14 μM, less than 13 μM, less than 12 μM, less than 11 μM, less than 10 μM, less than 9 μM, less than 8 μM, less than 7 μM, less than 6 μM, less than 5 μM, less than 4 μM, less than 3 μM, less than 2 μM, less than 1 μM, or less than 0.5 μM.
[0167] In any method for evaluating or identifying cells with certain characteristics as described herein, for example, to susceptibility to protein degradation inhibitors, one or more cells can be screened simultaneously in a high-throughput format. For example, cells can be cultured with separate aliquots, for example, in different holes of a multi-well plate, wherein every kind of independent cell aliquot is cultivated or selected under different conditions. Different conditions can include protein degradation inhibitors of varying concentrations, additional selection steps, or import different exogenous nucleic acids. In such embodiments, the comparison of the value of one or more parameters related to cell function determined from each aliquot can be used to identify cells, select or be classified as high producers, or for further developing cells into high production cell lines.
[0168] Products and nucleic acids encoding them
[0169] Provided herein are methods for identifying, selecting or generating cells or cell lines capable of producing high product yields. Products encompassed by the present disclosure include, but are not limited to, molecules, nucleic acids, polypeptides (e.g., recombinant polypeptides) or their heterocomplexes that can be produced by, for example, expression in cells. In some embodiments, cells are engineered or modified to produce products. Such modifications include the introduction of molecules that control or cause product production. For example, cells are modified by importing exogenous nucleic acids encoding polypeptides (e.g., recombinant polypeptides), and cells are cultured under conditions suitable for producing (e.g., expressing and secreting) polypeptides (e.g., recombinant polypeptides). In another example, cells are modified by importing exogenous nucleic acids that control, for example, increase the expression of polypeptides endogenously expressed by cells, so that the cells produce a polypeptide that is higher in level or amount than, for example, endogenously produced in unmodified cells.
[0170] In embodiments, the cells or cell lines identified, selected or produced by the methods described herein produce products, such as recombinant polypeptides, that can be used to treat medical conditions, disorders or diseases. Examples of medical conditions, disorders or diseases include, but are not limited to, metabolic diseases or disorders (e.g., metabolic enzyme deficiencies), endocrine disorders (e.g., hormone deficiencies), hemostasis, thrombosis, hematopoietic disorders, lung diseases, gastrointestinal diseases, immunomodulation (e.g., immunodeficiency), infertility, transplantation, cancer and infectious diseases.
[0171] In some embodiments, the product is an exogenous protein, such as a protein that is not naturally expressed by the cell. The product can be a therapeutic protein or a diagnostic protein, such as can be used for drug screening. The therapeutic or diagnostic protein can be an antibody molecule, such as an antibody or antibody fragment, a fusion protein, a hormone, a cytokine, a growth factor, an enzyme, a glycoprotein, a lipoprotein, a reporter protein, a therapeutic peptide, or any structural and / or functional fragment or hybrid of these.
[0172] In one embodiment, the product (e.g., a recombinant polypeptide) is an antibody molecule. Products included herein include diagnostic and therapeutic antibody molecules. Diagnostic antibody molecules include antibodies that can be used for imaging techniques, such as monoclonal antibodies or antibody fragments thereof. Therapeutic antibody molecules are suitable for administration to a subject, such as for the treatment or prevention of a disease or condition.
[0173] Antibody molecules are proteins or polypeptide sequences derived from immunoglobulin molecules that specifically bind to antigens. In one embodiment, antibody molecules are full-length antibodies or antibody fragments. Antibodies and polymorphic proteins can be polyclonal or monoclonal, multi-chain or single-chain, or complete immunoglobulins, and can be derived from natural sources or recombinant sources. Antibodies can be tetramers of immunoglobulin molecules. In one embodiment, antibodies are monoclonal antibodies. Antibodies can be people or humanized antibodies. In one embodiment, antibodies are IgA, IgG, IgD or IgE antibodies. In one embodiment, antibodies are IgG1, IgG2, IgG3 or IgG4 antibodies.
[0174] "Antibody fragment" refers to at least a portion of an intact antibody or a recombinant variant thereof, and refers to an antigen binding domain, such as an antigen-determining variable region of an intact antibody, which is sufficient to confer recognition and specific binding of the antibody fragment to a target, such as an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments, scFv antibody fragments, linear antibodies, single domain antibodies such as sdAb (VL or VH), camelid VHH domains, and multispecific antibodies formed from antibody fragments, such as a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region, and isolated CDRs or other epitope-binding fragments of antibodies. Antigen binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs and bis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology 23: 1126-1136, 2005). Antigen binding fragments can also be transplanted into scaffolds based on polypeptides such as type III fibronectin (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide minibodies).
[0175] Exemplary products, e.g., polypeptides, e.g., recombinant polypeptides, produced in the methods or cells described herein are provided in the table below.
[0176] Table 1. Exemplary products
[0177]
[0178]
[0179]
[0180] In another embodiment, the product is a bispecific molecule. As described herein, bispecific molecules include molecules that can bind to two or more different antigens or targets. In one embodiment, the bispecific molecule comprises an antibody fragment. In one embodiment, the bispecific molecule comprises a bispecific antibody, a bispecific antibody fusion protein or a bispecific antibody conjugate, a bispecific T cell binder (BiTE) molecule, a dual affinity retargeting (DART) molecule, a dual-acting Fab (DAF) molecule, a nanobody or other arrangements of an antibody fragment, which results in a molecule with the ability to recognize or bind to two different antigens.
[0181] Table 2. Exemplary products, e.g., bispecific molecules
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
[0188] Other exemplary therapeutic or diagnostic proteins include, but are not limited to, any of the proteins described in Tables 1-10 of Leader et al., “Protein therapeutics: a summary and pharmacological classification”, Nature Reviews Drug Discovery, 2008, 7:21-39 (incorporated herein by reference); or any conjugate, variant, analog or functional fragment of the recombinant polypeptide described herein.
[0189] Other recombinant products include non-antibody scaffolds or alternative protein scaffolds, such as but not limited to: DARPins, affibodies and adnectins. Such non-antibody scaffolds or alternative protein scaffolds can be engineered to recognize or bind one or two or more, such as 1, 2, 3, 4 or 5 or more different targets or antigens.
[0190] Also provided herein are nucleic acids, such as coded products, such as polypeptides, such as exogenous nucleic acids of recombinant polypeptides as described herein. Nucleic acid sequences encoding desired recombinant polypeptides can be obtained using recombinant methods known in the art, such as, for example, by screening libraries from cells expressing desired nucleic acid sequences (such as genes), by obtaining the nucleic acid sequences from known vectors containing nucleic acid sequences, or by using standard techniques to separate directly from cells and tissues containing nucleic acid sequences. Alternatively, nucleic acids encoding recombinant polypeptides can be synthesized, rather than cloned. Recombinant DNA technology and technology are highly advanced and well established in the art. Therefore, a person of ordinary skill with knowledge of the amino acid sequence of a recombinant polypeptide as described herein can easily envision or produce nucleic acid sequences encoding recombinant polypeptides.
[0191] In some embodiments, exogenous nucleic acid controls the expression of products expressed endogenously by host cells. In such embodiments, exogenous nucleic acid comprises one or more nucleic acid sequences (also referred to herein as "endogenous product transactivation sequences") that increase the expression of endogenous products. For example, the nucleic acid sequence that increases the expression of endogenous products comprises a constitutively active promoter or a stronger promoter, such as increasing the transcription at the desired site, such as increasing the expression of the desired endogenous gene product. After importing an exogenous nucleic acid comprising an endogenous product transactivation sequence, the exogenous nucleic acid is integrated into the chromosome genome of the cell, for example, at a preselected position near the genomic sequence encoding the endogenous product, so that the endogenous product transactivation sequence increases the transactivation or expression of the desired endogenous product. For modifying cells, other methods such as importing exogenous nucleic acids to increase the expression of endogenous products are described in, for example, U.S. Patent No. 5,272,071, which is incorporated herein by reference in its entirety.
[0192] The expression of the products described herein is generally achieved by operably linking a nucleic acid encoding a recombinant polypeptide or portion thereof to a promoter and incorporating the construct into an expression vector. The vector may be suitable for replication and integration of eukaryotic or prokaryotic organisms. Typical cloning vectors contain other regulatory elements, such as transcription and translation terminators, initiation sequences, and promoters that can be used to regulate expression of the desired nucleic acid sequence.
[0193] The nucleotide sequence described herein of the nucleotide sequence that can control the expression of endogenous product (for example recombinant polypeptide) or comprise can be cloned into many types of vectors.For example, nucleic acid can be cloned into vector, and described vector includes but is not limited to plasmid, phagemid, phage derivative, animal virus and cosmid.The carrier of particular interest includes expression vector, replication vector, probe generation vector and sequencing vector.In embodiments, expression vector can be provided to cell in the form of viral vector.Viral vector technology is well known in the art, and is described in for example Sambrook etc., 2012, MOLECULAR CLONING:A LABORATORY MANUAL, Vol. 1-4, Cold Spring Harbor Press, NY), and other virology and molecular biology manuals.The virus that can be used as vector includes but is not limited to retrovirus, adenovirus, adeno-associated virus, herpes virus and slow virus. Typically, suitable vectors contain an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers (e.g., WO 01 / 96584; WO 01 / 29058; and U.S. Pat. No. 6,326,193). Virus-derived vectors are suitable tools for achieving long-term gene transfer because they allow long-term, stable integration of transgenes and their propagation in daughter cells.
[0194] The vector may also include, for example, a signal sequence to promote secretion, a polyadenylation signal and a transcription terminator (e.g., from the bovine growth hormone (BGH) gene), elements allowing episomal replication and replication in prokaryotes (e.g., the SV40 origin and ColE1 or other elements known in the art) and / or elements allowing selection, such as a selectable marker or a reporter gene.
[0195] In one embodiment, the vector comprising a nucleic acid sequence encoding a polypeptide (e.g., LMM or a recombinant polypeptide) further comprises a promoter sequence, which is responsible for recruiting a polymerase to enable transcription initiation to express a polypeptide, such as LMM or a recombinant polypeptide. In one embodiment, a promoter sequence suitable for the methods described herein is usually combined with an enhancer to drive a large amount of transcription and thus deliver a large copy of the target exogenous mRNA. In one embodiment, the promoter comprises a cytomegalovirus (CMV) major immediate early promoter (Chernajovsky, Moryetal.1984), derived from its homonymous virus or a promoter derived therefrom. Several other less common viral promoters have been successfully used to drive transcription after inclusion in an expression vector, including Rous sarcoma virus long terminal repeat (RSV-LTR) and Moloney murine leukemia virus (MoMLV) LTR (Papadakis, Nicklintal.2004). In another embodiment, a specific endogenous mammalian promoter can be used to drive constitutive transcription of a gene of interest (Pontiller, Grossetal.2008). The CHO-specific Chinese hamster elongation factor 1-α (CHEF1α) promoter has provided a high-yield alternative to viral-based sequences (Deer, Allison 2004). In addition to the promoter, the vectors described herein also contain the enhancer region described above; a specific nucleotide motif region near the core promoter that can recruit transcription factors to regulate the transcription rate (Riethoven 2010). Similar to the promoter sequence, these regions are often derived from viruses and are included within the promoter sequence, such as CMV and SV40 enhancer sequences, or can be included, such as adenovirus-derived sequences (Gaillet, Gilbert et al. 2007).
[0196] In one embodiment, the vector comprising a nucleic acid sequence encoding a product (e.g., a polypeptide, e.g., a recombinant polypeptide) as described herein further comprises a nucleic acid sequence encoding a selection marker. In one embodiment, the selection marker comprises glutamine synthase (GS); dihydrofolate reductase (DHFR), e.g., an enzyme that confers resistance to methotrexate (MTX); or an antibiotic marker, e.g., an enzyme that confers antibiotic resistance, e.g., hygromycin, neomycin (G418), zeocin, puromycin, or blasticidin. In another embodiment, the selection marker comprises a Selexis selection system (e.g., SUREtechnologyPlatform). TM and Selexis Genetic Elements TM , commercially available from Selexis SA) or Catalant select systems or are compatible therewith.
[0197] In one embodiment, the vector comprising the nucleic acid sequence encoding the recombinant product described herein comprises a selection marker that can be used to identify one or more cells, and the cell comprises the nucleic acid encoding the recombinant product described herein. In another embodiment, the selection marker can be used to identify one or more cells that the nucleic acid sequence encoding the recombinant product is integrated into the genome, as described herein. The identification of one or more cells that have integrated the nucleic acid sequence encoding the recombinant protein can be used to select and engineer cells or cell lines that stably express the product.
[0198] Vectors suitable for use are commercially available and include those used with the GS Expression System TM GS Xceed TM Gene Expression System, or the Vectors related to CHO GS technology, such as those described in Fan et al., Pharm. Bioprocess. (2013); 1 (5): 487-502 (which is incorporated herein by reference in its entirety). The GS expression vector comprises a GS gene or a functional fragment thereof (e.g., a GS minigene), and one or more, such as 1, 2 or 3 or more, efficient transcription cassettes for expressing a gene of interest, such as a nucleic acid encoding a recombinant polypeptide described herein. The GS minigene comprises intron 6 of the genomic CHO GS gene, for example, consisting of intron 6 of the genomic CHO GS gene. In one embodiment, the GS vector comprises a GS gene operably linked to an SV40L promoter and one or two polyA signals. In another embodiment, the GS vector comprises a GS gene operably linked to an SV40E promoter, SV40 splicing and polyadenylation signals. In such embodiments, for example, a transcription cassette for expressing a gene of interest or a recombinant polypeptide described herein comprises an hCMV-MIE promoter and a 5' non-translated sequence from an hCMV-MIE gene including the first intron. Other vectors can be constructed based on the GS expression vector, for example, in which other selection markers are substituted for the GS gene in the expression vector described herein.
[0199] Vectors suitable for the methods described herein include, but are not limited to, other commercially available vectors, such as pcDNA3.1 / Zeo, pcDNA3.1 / CAT, pcDNA3.3TOPO (Thermo Fisher, formerly Invitrogen); pTarget, HaloTag (Promega); pUC57 (GenScript); pFLAG-CMV (Sigma-Aldrich); pCMV6 (Origene); pEE12 or pEE14 (Lonza Biologics), or pBK-CMV / pCMV-3Tag-7 / pCMV-Tag2B (Stratagene).
[0200] Cells and cell culture
[0201] In one aspect, the present disclosure relates to methods for evaluating, classifying, identifying, selecting or generating cells or cell lines that produce products (e.g., recombinant polypeptides as described herein). In another aspect, the present invention relates to methods and compositions for evaluating, classifying, identifying, selecting or generating cells or cell lines with improved, e.g., increased productivity and product quality.
[0202] In embodiments, the cell is a mammalian cell. In other embodiments, the cell is a cell other than a mammalian cell. In one embodiment, the cell is from a mouse, a rat, a Chinese hamster, a Syrian hamster, a monkey, an ape, a dog, a horse, a ferret, or a cat. In embodiments, the cell is a mammalian cell, such as a human cell or a rodent cell, such as a hamster cell, a mouse cell, or a rat cell. In another embodiment, the cell is from a duck, a parrot, a fish, an insect, a plant, a fungus, or a yeast. In one embodiment, the cell is an archaebacterium. In one embodiment, the cell is an Actinobacteria species, such as Mycobacterium tuberculosis.
[0203] In one embodiment, the cell is a Chinese hamster ovary (CHO) cell. In one embodiment, the cell is a CHO-K1 cell, a CHO-K1 SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knockout cell, a CHOFUT8 GS knockout cell, a CHOZN or a CHO derived cell. A CHO GS knockout cell (e.g., a GSKO cell) is, for example, a CHO-K1SV GS knockout cell (Lonza Biologics, Inc.). A CHO FUT8 knockout cell is, for example, CHOK1SV (Lonza Biologics, Inc.).
[0204] In another embodiment, the cell is Hela, HEK293, HT1080, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK (baby hamster kidney cells), VERO, SP2 / 0, NS0, YB2 / 0, Y0, EB66, C127, L cells, COS, such as COS1 and COS7, QC1-3, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SVGS-KO, CHOS, CHO DG44, CHO DXB11, and CHOZN, or any cell derived therefrom. In one embodiment, the cell is a stem cell. In one embodiment, the cell is a differentiated form of any cell described herein. In one embodiment, the cell is a cell derived from any primary cell in culture.
[0205] In one embodiment, the cell is any cell described herein, comprising an exogenous nucleic acid encoding a recombinant polypeptide, eg, expressing a recombinant polypeptide, eg, a recombinant polypeptide selected from Table 1 or 2.
[0206] In one embodiment, the cell culture is carried out as a batch culture, a fed-batch culture, a draw and fill culture, or a continuous culture. In one embodiment, the cell culture is a suspension culture. In one embodiment, the cells or cell culture are placed in vivo to express the recombinant polypeptide, for example, in a model organism or a human subject.
[0207] In one embodiment, the culture medium does not contain serum. Serum-free and protein-free culture media are commercially available, for example from Lonza Biologics.
[0208] Suitable media and culture methods for mammalian cell lines are well known in the art, as described, for example, in US Pat. No. 5,633,162. Examples of standard cell culture media for laboratory flasks or low-density cell culture and adapted to the needs of specific cell types are, for example: Roswell Park Memorial Institute (RPMI) 1640 medium (Morre, G., The Journal of the American Medical Association, 199, p. 519f. 1967), L-15 medium (Leibovitz, A. et al., Amer. J. of Hygiene, 78, 1 p. 173ff., 1963), Dulbecco's modified Eagle medium (DMEM), Eagle's minimum essential medium (MEM), Ham's F12 medium (Ham, R. et al., Proc. Natl. Acad. Sc. 53, p. 288 ff. 1965) or Iscoves' modified DMEM lacking albumin, transferrin and phosphatidylcholine (Iscoves et al., J. Exp. med. 1, p. 923ff., 1978). For example, Ham's F10 or F12 medium is specifically designed for CHO cell culture. Other culture media particularly suitable for CHO cell culture are described in EP-481 791. It is known that such culture media can be supplemented with fetal bovine serum (FBS, also known as fetal calf serum FCS), which provides a natural source of various hormones and growth factors. Cell culture of mammalian cells is now a routine procedure well described in scientific textbooks and manuals, which is covered in detail in, for example, R. Ian Fresney, Culture of Animal cells, Handbook, 4th edition, Wiley-Liss / NY, 2000.
[0209] Other suitable culture methods are known to the skilled artisan and may depend on the recombinant polypeptide product and the host cell used. It is within the skills of the ordinary technician to determine or optimize conditions suitable for expression and production of a recombinant polypeptide to be expressed by a cell.
[0210] In one aspect, the cell or cell line comprises an exogenous nucleic acid encoding a product, such as a recombinant polypeptide. In one embodiment, the cell or cell line expresses a product, such as a therapeutic or diagnostic product. Methods for genetically modifying or engineering cells to express a desired polypeptide or protein are well known in the art and include, for example, transfection, transduction (e.g., viral transduction) or electroporation.
[0211] Physical methods for introducing nucleic acids (e.g., exogenous nucleic acids or vectors described herein) into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, etc. Methods for producing cells containing vectors and / or exogenous nucleic acids are well known in the art. See, e.g., Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, Vol. 1-4, Cold Spring Harbor Press, NY).
[0212] Chemical methods for introducing nucleic acid (e.g., exogenous nucleic acid or vector as described herein) into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle). Other methods of nucleic acid targeted delivery of the prior art are available, such as delivery of polynucleotides with targeted nanoparticles or other suitable submicron-sized delivery systems.
[0213] In an embodiment, it is desirable to integrate the exogenous nucleic acid into the nucleic acid of the host cell, such as the genome or chromosomal nucleic acid of the host cell. The method for determining whether the integration of the exogenous nucleic acid into the genome of the host cell has occurred may include a GS / MSX selection method. The GS / MSX selection method uses the complementation of the recombinant GS gene to the glutamine auxotrophy to select the high level expression of the protein from the cell. In short, the GS / MSX selection method includes a nucleic acid encoding glutamine synthase on a vector, wherein the vector comprises an exogenous nucleic acid encoding a recombinant polypeptide product. The administration of methionine sulfoximide (MSX) selects cells that have stably integrated the exogenous nucleic acid encoding both the recombinant polypeptide and GS into the genome. Since GS can be endogenously expressed by some host cells (e.g., CHO cells), the concentration and duration of selection with MSX can be optimized to identify high-yield cells, wherein the exogenous nucleic acid encoding the recombinant polypeptide product is stably integrated into the host genome. GS selection and its system are further described in Fan et al., Pharm. Bioprocess. (2013); 1 (5): 487-502 (which is incorporated herein by reference in its entirety).
[0214] Other methods for identifying and selecting cells that have stably integrated the exogenous nucleic acid into the host cell genome may include, but are not limited to, including a reporter gene on the exogenous nucleic acid and assessing the presence of the reporter gene in the cells, and PCR analysis and detection of the exogenous nucleic acid.
[0215] In one embodiment, the cells selected, identified or produced using the methods described herein are capable of producing a higher protein product yield than cells selected using only a stable expression selection method, such as integration of an exogenous nucleic acid encoding a recombinant polypeptide. In one embodiment, cells selected, identified or produced using the methods described herein produce 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or 10-fold or more of a product (e.g., a recombinant polypeptide) compared to cells not contacted with a protein degradation inhibitor or cells that only select stable expression (e.g., integration) of an exogenous nucleic acid encoding a recombinant polypeptide.
[0216] Assess, classify, select or identify cells
[0217] In one aspect, the disclosure features methods for assessing a cell (e.g., a candidate cell) for product production (e.g., recombinant polypeptide production) capabilities. The results of such assessments can provide information that can be used to select or identify cells for use in generating cells or cell lines that are high-yield cells or cell lines. In another embodiment, in response to an assessment as described herein, a cell or cell line can be classified as, for example, a cell or cell line with high productivity.
[0218] A high producing cell or cell line is capable of producing a higher yield of a recombinant polypeptide product compared to a reference cell or a cell that has not been selected or produced by the methods described herein. In one embodiment, the high producing cell line is capable of producing 25 mg / L, 50 mg / L, 100 mg / L, 200 mg / L, 300 mg / L, 400 mg / L, 500 mg / L, 600 g / L, 700 g / L, 800 g / L, 900 g / L, 1 g / L, 2 g / L, 3 g / L, 4 g / L, 5 g / L, 10 g / L, 15 g / L, 20 g / L, 25 g / L, 30 g / L, 35 g / L, 40 g / L, 45 g / L, 50 g / L, 55 g / L, 60 g / L, 65 g / L, 70 g / L, 75 g / L, 80 g / L, 85 g / L, 90 g / L, 95 g / L, or 100 g / L or more of a product, e.g., a recombinant polypeptide product. In one embodiment, the high yield cell line produces 100mg / L, 200mg / L, 300mg / L, 400mg / L, 500mg / L, 600g / L, 700g / L, 800g / L, 900g / L, 1g / L, 2g / L, 3g / L, 4g / L, 5g / L, 10g / L, 15g / L, 20g / L, 25g / L, 30g / L, 35g / L, 40g / L, 45g / L, 50g / L, 55g / L, 60g / L, 65g / L, 70g / L, 75g / L, 80g / L, 85g / L, 90g / L, 95g / L or 100g / L or more of a product, such as a recombinant polypeptide product. The amount of the product produced can vary with cell type (e.g., species) and recombinant polypeptide to be expressed. For example, a high producing cell is capable of producing at least 1 g / L, 2 g / L, 5 g / L, 10 g / L, 15 g / L, 20 g / L, or 25 g / L or more of a recombinant polypeptide, e.g., as described herein.
[0219] In embodiments where the product is difficult to express, the high-yielding cells can produce a lower concentration of product, such as less than 1 g / L, however, the productivity is higher or increased compared to the productivity observed for cells that have not been contacted with the protein degradation inhibitor. For example, the level, amount or quantity of the product produced by the identified or selected cells is increased, such as by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or 100 times or more, compared to the level, amount or quantity produced by cells that have not been contacted with the protein degradation inhibitor.
[0220] The method for evaluating cells described herein includes evaluating the impact of protein degradation inhibitors on one or more parameters related to cell function.Parameters related to cell function include but are not limited to cell survival, culture viability, proliferation capacity, the ability to produce products and protein degradation. In an embodiment, the impact value of protein degradation inhibitors on one or more parameters related to cell function is compared with a reference value to determine the impact of the inhibitor on the parameters related to cell function, for example, for determining whether contacting cells with inhibitors causes an increase or decrease in one of the parameters related to cell function. In one embodiment, in response to determining an increase or decrease in one or more parameters related to cell function, cells can be selected or identified for development as cell production systems. In one embodiment, in response to determining an increase or decrease in one or more parameters related to cell function, cells can be identified as high-yield cells, for example, cells that can produce higher product yields.
[0221] In any of the embodiments described herein, the reference value can be the value of the effect of the protein degradation inhibitor on a parameter associated with cell function of a reference cell (e.g., a cell with a predetermined productivity). Alternatively or additionally, in any of the embodiments described herein, the reference value can be the value of the parameter associated with cell function of the same cell tested, where the cell has not been contacted with the inhibitor, such as measuring the parameter value before contacting the cell with the protein degradation inhibitor, or the value of the parameter associated with cell function of a different aliquot of cells that have not been contacted with the protein degradation inhibitor.
[0222] In one embodiment, cell survival can be measured by measuring or quantifying apoptosis, for example, the number or amount of cells killed or dead in response to the concentration of protein degradation inhibitors as described herein. The increase in cell survival includes the remaining cells after contacting with the protein degradation inhibitor, such as an increase in the number of intact cells or living cells of 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1 times, 2 times, 3 times, 4 times or 5 times or more. Alternatively, the increase in cell survival includes a decrease in the number of apoptotic cells after contacting with the protein degradation inhibitor by 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. Methods for detecting cell survival or apoptosis are known in the art, such as the annexin V assay, and are described in the embodiments herein.
[0223] In one embodiment, culture viability can be measured by measuring or quantifying the number or amount of living cells, such as living cells in a culture or cell colony, or having characteristics associated with viability, such as proliferation markers, cells of intact DNA, or cells that do not display apoptosis markers. The increase in culture viability includes cells remaining after contact with a protein degradation inhibitor, such as an increase of 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1 times, 2 times, 3 times, 4 times or 5 times or more of intact cells or living cells. Methods for determining culture viability are known in the art and are described in Examples 1 and 3 herein. Other methods for assessing culture viability include, but are not limited to, trypan blue exclusion, followed by counting using a hemocytometer or Vi-CELL (Beckman-Coulter). Other methods for assessing culture viability can include determining the viable biomass, and include using radio frequency impedance or capacitance (e.g., as described in Carvell and Dowd, 2006, Cytotechnology, 50:35-48), or using Raman spectroscopy (e.g., as described in Moretto et al., 2011, American Pharmaceutical Review, Vol. 14).
[0224] In one embodiment, the ability of cell proliferation can be measured by quantitative or counting cell number, cell doubling or cell growth rate. Alternatively, the genomic content of the cell can be analyzed (e.g., DNA replication) (e.g., by flow cytometry analysis), or proliferation markers, such as Ki67, the phosphorylated cell cycle protein-CDK complex involved in the cell cycle is identified to proliferate cells. The increase in proliferation ability includes increasing the number of cells or the number of cells expressing proliferation markers after the cells are contacted with a protein degradation inhibitor by 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1 times, 2 times, 3 times, 4 times or 5 times or more. Alternatively, the increase in proliferation ability includes increasing the doubling or growth rate of the cells after the cells are contacted with a protein degradation inhibitor by 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1 times, 2 times, 3 times, 4 times or 5 times or more.
[0225] The methods provided herein can be used to identify, select or generate cells or cell lines with improved ability to produce recombinant polypeptides (e.g., products). In one embodiment, the methods provided herein can also be used to identify, select or generate cells or cell lines that produce improved recombinant polypeptide quality.
[0226] In one embodiment, the ability of a cell to produce a product can be measured by the amount or concentration of the product produced by assay or quantification. The ability to produce a product increases by 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1 time, 2 times, 3 times, 4 times or 5 times or more of protein output after contacting the cell with a protein degradation inhibitor.
[0227] In one embodiment, the quality of the product (e.g., recombinant polypeptide expressed) can be measured by measuring or quantifying the amount or concentration of correctly folded products, functional products, or non-aggregated products. The improvement of the quality of the product produced by the cell includes increasing the amount or concentration of correctly folded products, functional products, or non-aggregated products (e.g., recombinant polypeptide expressed) by 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1 times, 2 times, 3 times, 4 times, or 5 times or more after the cell is contacted with a protein degradation inhibitor.
[0228] The method of measuring the protein output of increase is well known to those skilled in the art. For example, the titer in tissue culture medium can be measured by ELISA to determine the increase of recombinant protein output on a small scale (Smales etc. 2004Biotechnology Bioengineering 88:474-488). It can also be quantitatively determined by ForteBio Octet, for example, for high-throughput determination of recombinant monoclonal antibody (mAb) concentration in culture medium (Mason etc. 2012Biotechnology Progress 28:846-855) or on a larger scale by protein A HPLC determination (Stansfield etc. 2007Biotechnology Bioengineering 97:410-424). Other methods for determining the output of product (for example, recombinant polypeptide as described herein) can refer to the time integral (IVC) of product in cell, particularly specific production rate (qP) and / or viable cell concentration of recombinant polypeptide. Recombinant polypeptide production or productivity (defined as the concentration of polypeptide in the culture medium) is a function of these two parameters (qP and IVC) calculated according to Porter et al. (Porter et al. 2010 Biotechnology Progress 26: 1446-1455). Methods for measuring protein yield are also described in further detail in the examples provided herein, such as Examples 1 and 5.
[0229] Methods for measuring the improved product quality produced by the cell line produced as described herein are known in the art. In one embodiment, the method for determining the fidelity of the primary sequence of the recombinant polypeptide product expressed is known in the art, such as mass spectrometry. The amount or concentration increase of the correctly folded product (such as the recombinant polypeptide expressed) can be determined by circular dichroism or the intrinsic fluorescence of the recombinant polypeptide expressed by assessment. Various functional assays can be used to test the increase of the amount or concentration of the functional product, which depends on the characteristic of the recombinant polypeptide. For example, antibodies can be tested by ELISA or other immunoaffinity assays.
[0230] Cell lines and methods for recombinant polypeptide production
[0231] The state of the art in both mammal and microorganism selection systems is to apply selection pressure on the transcription level of DNA to RNA. Interested gene is closely linked to selection marker, and the high level expression of selection marker may lead to the high expression of interested gene. Cells expressing high level selection marker can survive and proliferate, and those cells that are unlikely to survive and proliferate are such as apoptosis and / or death. In this way, cell colony enrichment can be performed with high level expression selection marker and hint with high level expression of interested gene cell. This method has been proved to be very successful for expressing direct protein.
[0232] However, for some proteins, the bottleneck of expression is not DNA being transcribed into RNA, but correct folding and, where necessary, post-translational modification of protein. The current selection system of targeted transcription does not exert pressure to select a good cell line in production and correct processing of protein. In fact, high-level transcription can aggravate the problem of downstream protein synthesis step by overloading the ability of cells to produce and process these proteins. The use of the selection system that applies selection pressure in the alternative stage of protein production can greatly improve the stringency of selection. Such selection systems can be referred to as orthogonal selection systems, because their mode of action does not depend on the prior art selection systems operating at the gene transcription level. These alternative selection systems can also be operated independently of each other, and are therefore orthogonal to each other. For example, the selection systems of targeted transcription, translation, post-translational modification and secretion may be independent of each other in mode of action. Orthogonal selection systems can be used together to increase the stringency of selection and hit multiple targets in selection.
[0233] The present invention is one example of an orthogonal selection system that operates at the level of protein folding and post-translational modification. However, other examples of orthogonal selection systems can be envisioned that work on the same broad principle of inhibiting the growth of cells that perform poorly in the protein expression step downstream of transcription within the population.
[0234] In one aspect, the disclosure provides methods for producing cells or cell lines for producing products (e.g., recombinant polypeptides). On the other hand, the disclosure provides methods for producing products (e.g., recombinant polypeptides described herein) using cells identified, classified, selected, or produced using the methods described herein. Any of the foregoing methods include assessing, identifying, classifying, or selecting cells as described herein, such as by contacting the cells with a protein degradation inhibitor to identify or generate cells with high product (e.g., recombinant polypeptide) production capacity. The methods herein increase the production of recombinant polypeptides, such as expression and / or secretion.
[0235] Without wishing to be bound by theory, it is believed that cells capable of higher productivity are less susceptible to protein degradation inhibitors, and therefore, contacting cells with a protein degradation inhibitor comprising an exogenous nucleic acid as described herein is believed to result in the selection of cells capable of higher productivity.
[0236] In one aspect, utilizing two or more selection steps, such as selecting for stable integration of exogenous nucleic acids and selecting for sensitivity to inhibited protein degradation, results in cells and cell lines that are more productive than cells produced by a single selection step. Thus, the invention features a method for producing highly productive cells, comprising:
[0237] i) providing a cell comprising an exogenous nucleic acid encoding a recombinant polypeptide product;
[0238] ii) applying a first selection pressure, e.g., selecting for a first property, e.g., selecting for cells having stably integrated the exogenous nucleic acid; and
[0239] iii) applying a secondary selection pressure, e.g., selecting for a secondary property, e.g., selecting for cells with a lower susceptibility to inhibition of protein degradation.
[0240] In an embodiment, the first selection pressure is applied before, at the same time as, or after the second selection pressure is applied. In one embodiment, the first selection pressure is applied before the second selection pressure. In one embodiment, the first selection pressure is completed before the second selection pressure is started. In one embodiment, the second selection pressure is applied before the first selection pressure. In one embodiment, the second selection pressure is completed before the first selection pressure is started. In one embodiment, the first selection pressure and the second selection pressure are applied simultaneously. In one embodiment, the application of the first and second selection pressures overlaps completely or partially. In one embodiment, the second selection pressure is started 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, or 168 hours or longer before the first selection pressure is completed. In one embodiment, the second selection pressure is started 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, or 168 hours or longer after the first selection pressure is completed.
[0241] In one embodiment, the first selection pressure comprises selecting for stable integration of exogenous nucleic acids, such as GS / MSX selection. In one embodiment, the second selection pressure comprises selecting for susceptibility to inhibition of protein degradation, including contacting cells with protein degradation inhibitors. In one embodiment, the protein degradation inhibitor is applied before, simultaneously with, or after the selection pressure, and the selection pressure comprises identifying cells with genomic integration comprising exogenous nucleic acids. In one embodiment, the protein degradation inhibitor is applied 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, or 168 hours or longer after completing the prior selection step to identify cells with genomic integration comprising exogenous nucleic acids.
[0242] In order to select the ability of producing recombinant polypeptide with improvement, and / or to have the mode of the cell of the ability of producing recombinant polypeptide with improved quality, selective pressure is applied.In one embodiment, every kind of selective pressure is applied, for example the first and / or second selective pressure as described herein reaches at least 24 hours, 48 hours, 72 hours, 96 hours or 120 hours or 168 hours.As described herein, the concentration of protein degradation inhibitor causes at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% or 70% culture viability, for example, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% or 70% cell number is cultivated after retaining in the presence of protein degradation inhibitor as described herein, for example survival. In some embodiments, the method herein, for example, particularly after applying two or more selection pressures, results in less than 20%, for example 15%, 10%, 5%, 1%, 0.5%, 0.1% or less total cells remaining after selection. Compared with the percentage of culture viability or cell survival in the absence of a protein degradation inhibitor, the percentage of culture viability or cell survival after selection in the presence of a protein degradation inhibitor as described herein is determined. The remaining viable cells after cultivation in the presence of a protein degradation inhibitor as described herein can be further cultured to produce a cell line.
[0243] In embodiments, the living cells retained after two selection pressures, such as selecting a stable integrant comprising an exogenous nucleic acid and selecting a low susceptibility to a protein degradation inhibitor, have an increased protein production capacity. For example, compared to cells that only apply a selection pressure or do not apply any selection pressure, the cell with increased protein production capacity produces 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times or more or at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more of the product, for example, a recombinant polypeptide.
[0244] In embodiments, the living cells retained after two selection pressures as described herein produce the improved quality of the recombinant polypeptide expressed. For example, the improved quality of the product includes one or more of the following: the ratio of the recombinant polypeptide expressed by more homogeneous products, correctly folded increases or the ratio of functional recombinant polypeptides increases, the ratio of the recombinant polypeptides gathered decreases. For example, compared with cells that only apply a kind of selection pressure or do not apply any selection pressure, the cell producing the improved product quality produces 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times or more or at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more correctly folded or functional recombinant polypeptides.
[0245] In one embodiment, the methods herein for generating a cell line with improved productivity or improved quality of produced product are useful with a pre-existing or commercial cell line expressing a recombinant polypeptide described herein, e.g., selected from Table 1 or 2. In such methods, cells are cultured in the presence of an effective concentration of a protein degradation inhibitor as described herein, suitable for identifying cells with improved productivity or improved product quality, e.g., a concentration of the protein degradation inhibitor that results in at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% culture viability, e.g., at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% of the number of cells remaining, e.g., alive, after culturing in the presence of a protein degradation inhibitor as described herein. In some embodiments, culturing cells in the presence of a protein degradation inhibitor described herein results in less than 20%, e.g., 15%, 10%, 5%, 1%, 0.5%, 0.1%, or less total cells remaining after culturing in the presence of a protein degradation inhibitor described herein. The remaining viable cells after culturing in the presence of a protein degradation inhibitor described herein can be further cultured to produce a cell line, e.g., an improved cell line.
[0246] In some embodiments, additional steps may be performed to improve the expression of the product, such as transcription, translation and / or secretion of the product, or the quality of the product, such as the correct folding and / or fidelity of the primary sequence. These additional steps include the introduction of agents that improve product expression or product quality. In one embodiment, the agent that improves product expression or product quality can be a small molecule, a polypeptide, or a nucleic acid encoding a polypeptide that improves protein folding, such as a chaperone. In one embodiment, the nucleic acid comprises an inhibitory nucleic acid, such as a microRNA or an lncRNA. In one embodiment, the agent that helps protein folding comprises a nucleic acid encoding a chaperone, such as BiP, PD1 or ERO1 (Chakravarthi & Bulleid 2004; Borth et al. 2005; Davis et al. 2000). Other additional steps to improve product yield and quality include overexpression of transcription factors such as SBP1 and ATF6 (Tigges & Fussenegger 2006; Cain et al. 2013; Ku et al. 2008) and overexpression of lectin binding chaperones such as calnexin and calreticulin (Chung et al., 2004). The overexpression of the medicaments that assist or improve protein folding and product quality and produce the protein described herein can be achieved by importing exogenous nucleic acids encoding proteins. In another embodiment, the reagents that improve product expression or product quality are small molecules that can be added to cell culture to increase product expression or product quality. In one embodiment, cells are cultured at a lower temperature, for example, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, or 10°C lower than the temperature at which cells are usually cultured.
[0247] Any method described herein can also include additional selection steps for identifying cells with high productivity or producing high-quality products. For example, FACS selection can be utilized to select and separate specific cells with desired characteristics, such as protein folding proteins, such as higher expression of chaperone proteins; Or improved product expression.
[0248] In one aspect, the present disclosure provides methods comprising steps for recovering or removing a recombinant polypeptide product. In embodiments where the recombinant polypeptide is secreted from a cell, the method may include steps for recovering, collecting or isolating the recombinant polypeptide from the cell, a cell population, or a culture medium in which the cells are cultured. In embodiments where the recombinant polypeptide is intracellular, purification of the recombinant polypeptide product includes separation of the recombinant polypeptide produced by the cell from any one or more of: host cell proteins, host cell nucleic acids, host cell lipids, and / or other debris from the host cell.
[0249] In embodiments, the methods described herein provide a substantially pure protein product. As used herein, "substantially pure" refers to being substantially free of hot raw materials, substantially free of nucleic acids, and / or substantially free of endogenous cell proteases and components from host cells, such as polymerases, ribosomal proteins, and chaperone proteins. Substantially pure protein products include, for example, less than 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of contaminating endogenous proteins, nucleic acids, or other macromolecules from host cells.
[0250] Methods for recovering and purifying products (e.g., recombinant polypeptides) are well established in the art. In order to recover the recombinant polypeptide product, a physical or chemical or physico-chemical method is used. The physical or chemical or physico-chemical method can be a filtration method, a centrifugation method, an ultracentrifugation method, an extraction method, a freeze-drying method, a precipitation method, a crystallization method, a chromatography method, or a combination of two or more thereof. In one embodiment, the chromatography method comprises one or more of the following: size exclusion chromatography (or gel filtration), ion exchange chromatography, such as anion or cation exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, and / or multivariate chromatography.
[0251] Example
[0252] The present invention is further described in detail by reference to the following experimental examples. These examples are provided for illustrative purposes only and are not intended to be limiting unless otherwise specified. Therefore, the present invention should never be interpreted as being limited to the following examples, but should be interpreted as including any and all variations that become apparent due to the teachings provided herein.
[0253] Without further description, it is believed that one of ordinary skill in the art can use the foregoing description and the following illustrative examples to make and utilize the compounds of the present invention and to practice the claimed methods. The following working examples specifically point out various aspects of the present invention and should not be construed as limiting the remainder of the disclosure in any way.
[0254] Example 1: Method
[0255] The methods and assays provided in this example are directed to evaluating the effects of protein degradation inhibitors on parameters associated with cell function, such as cell survival and culture viability. These methods and assays were used in the experiments described in the following examples.
[0256] Inhibitor killing curves for 96DWP forms
[0257] 4x 10 696 deep well plates (Nunc) were inoculated with 300 μl per well of each cell / ml for analysis of proteasome and ERAD inhibitors. For each in the cell line group, triplicate wells were generated for each inhibitor. 1 μl of each inhibitor stock solution was added to each well so that the final concentration was 0.05 μM epoxomicin, 0.5 μM MG-132 and 10 μM eeyarestatin I. The plate was incubated at 36.5°C with a shaking speed of 375 rpm in the case of 5% CO2 and 90% humidity until the appropriate 24 hour time point. 100 μl of pore volume was combined with 900 μl PBS, and cell counting was performed using a ViCell device. The remaining 200 μl was centrifuged at 1000 rpm for 5 minutes, and the supernatant and pellet were stored at -20°C and then further analyzed.
[0258] Proteasome activity analysis
[0259] 5 x 10 cells were isolated from the desired cell line by centrifuging the desired culture volume at 1000 rpm for 5 minutes. 6Cell pellets were prepared from 100 cells. The pellets were then stored at -20 °C until activity was assessed. The pellets were resuspended in lysis buffer (20 mM HEPESNaOH pH 7.2, 100 mM NaCl, 10 mM sodium β-glycerophosphate, 0.5% w / v Triton X-100). Bradford assay was then performed to determine the total protein in the lysate material, and the volume required for each reaction to obtain 100 μg of total protein was calculated. Multiple pellets were merged when necessary to ensure sufficient material for active probe assessment and subsequent inhibitor attack. Bradford assay was repeated for the merged material. 100 μg of protein was combined with 1 μl of probe or DMSO, and the reaction volume was made up to 200 μl with lysis buffer. The mixture was vortexed and shaken in the dark for 1 hour at room temperature (wrapped in foil). 1 ml of ice-cold 100% acetone was then added, vortexed, and then rotated at 13000 rpm for 5 minutes. The acetone was removed and the pellet was resuspended in 20 μl 2xSDS sample buffer. The samples were heated at 95°C for 5 minutes with occasional shaking and then briefly centrifuged at 13,000 rpm and then stored at -20°C before further analysis. The inhibitor challenge with epoxomicin was repeated with samples from the same lysate material. The reaction mixture was prepared in the same manner as before with 100 μg of protein and 1 μl of probe, with a final reaction volume of 200 μl. However, before adding the probe to the reaction, 1 μl of 50 μM or 20 μM epoxomicin was added and the reaction was incubated for 30 minutes in the dark at room temperature with shaking. After pre-incubation with the inhibitor, the probe was added and the reaction was continued as before for active probe evaluation. The samples were prepared as before using acetone precipitation and stored at -20°C until analysis. A 20 μl volume was loaded onto a 14% SDS-PAGE resolving gel with a 5% stacking gel. Before loading the gel, the samples were heated at 95°C for another 5 minutes and briefly centrifuged at 13,000 rpm. Gel was run for about 1 hour at 200V until complete. Then the fluorescence of the gel was analyzed using Typhoon 9400. RUB1001 probe was analyzed using Cy2 (filter: 520BP40, laser: blue 2 (488nm), sensitivity: normal). Probes MV151, MVB003, MVB072, RUB1018 and no probe were analyzed using Cy3 (filter: 580BP30, laser: green (532nm), sensitivity: normal), with a typical image resolution of 100 microns and 600 PMT. After the fluorescence analysis, the gel was placed in Coomassie dye overnight, and placed in a decolorizer the next day to provide a loading control for total protein.
[0260] Generation of polyclonal stable pools for cell line establishment experiments
[0261] Electroporation was performed in the GSKO suspension cell line. The culture was counted in mid-exponential phase and the remaining culture was centrifuged at 1000 rpm and the supernatant removed. 1 x 10 cells were required per electroporation cuvette in a volume of 700 μl. 7 Cells. Therefore, the pellet was resuspended to reach the cell concentration required for the number of electroporations. Electroporation was performed using 20 μg of linearized plasmid at 300V, a capacitance of 900 μF and a cup with a 4 mm gap. 20 ml of fresh culture medium was added to each cup, wherein the cup was rinsed with 2 ml of this volume. For cell line construction experiments, all electroporations were then combined to give a final volume of 300 ml. This was thoroughly mixed and then distributed in 10 ml volumes between 30x T75 tissue culture flasks. The flasks were then statically incubated at 36.5°C in the presence of 5% CO2. 24 hours after transfection, a glutamine synthase inhibitor (MSX) was added to provide selection of cells that successfully took up the plasmid and expressed the selection marker GS. A 5 ml volume of MSX stock solution with CD-CHO culture medium was added to give a final culture concentration of 25, 37.5 or 50 μM MSX. The addition of proteasome inhibitors was then performed at the appropriate time point after MSX selection, as determined by the experimental layout design detailed in Table 3. Filter-sterilized DMSO was added as a control, where no drug was required in the combination. The cultures were then incubated statically at 36.5°C and 5% CO2 for approximately two weeks after the addition of MSX. Viability counts were performed when an increase in cell concentration was observed in the culture or at least weekly. Once at least 0.2 x 10 6 At a viable cell concentration of 10 cells / ml, the culture was transferred to a 20 ml shake flask culture at 36.5°C and 5% CO2 with shaking at 140 rpm. From this point on, routine subculture was performed every 3-4 days.
[0262] Table 3: In vitro optimal response surface design
[0263]
[0264]
[0265] Enzyme-linked immunosorbent assay (ELISA) of supernatant samples to determine antibody concentration
[0266] AffiniPure F(ab')2 fragment goat anti-human IgG Fc fragment specific (minimal cross-reactivity to bovine, horse, mouse serum proteins) (Jackson ImmunoResearch Laboratories Inc) was diluted in coating buffer (15 mM Na2CO3 and 35 mM NaHCO3, pH 9.7) to give a concentration of 2.2 μg / ml. 100 μl of the stock solution was then used to coat each well of a 96-well plate (Nunc). The plate was covered with foil and stored overnight at 4°C. Plates were washed twice in wash buffer (0.1M NaCl, 8.1mM Na2HPO4, 2.4mM NaH2PO4.H2O, 12.7mM EDTA, 0.02% v / v Tween-20 and 1% L-butanol, pH 7.2), then 200 μl of blocking solution (15mM Na2CO3 and 35mM NaHCO3, 0.5% w / v casein in pH 9.7) was added to each well and incubated at room temperature for 1 hour with shaking. IgG standards of human IgG reagent grade (Sigma) were prepared by serial dilution in sample buffer (0.1M Tris-HCl, 0.1M NaCl and 0.02% v / v Tween-20, pH 7.0) to obtain a range of 250ng / ml-3.9ng / ml. Serial dilutions of supernatant samples in sample buffer were also performed. After blocking, the plate is washed twice in washing buffer, and then 100 μl of sample / standard is added to the relevant well. The plate is then incubated for another 1 hour at room temperature with shaking. The plate is washed twice, and then 100 μl / well of secondary antibody solution (anti-human κ light chain (bound and free) HRP conjugate (Sigma) generated in goats diluted 1:10000 in washing buffer) is added. After adding the secondary antibody, the plate is incubated for 1 hour at room temperature with shaking. The plate is washed again and ready-made TMB substrate (Cellsignalling technology#7004) (100 μl / well) is added. Once significant blue coloring of the standard occurs, 50 μl / well of 2.5M H2SO4 is used to terminate the reaction. The optical density of each well is then measured at 450nm. The concentration of the supernatant sample is then determined from the standard curve of known IgG concentration.
[0267] Protein A HPLC determination of antibody concentration
[0268] HPLC was performed with a protein A column using Chemstation software and an Agilent 1260 instrument according to Lonza standard operating procedures. Protein A HPLC standards (batch number L27336 / 07 / 02) at a concentration of 1008 mg / L were used, diluted 1 / 2 with binding buffer. Universal IAC (batch number L27336 / 7 / 1) at a concentration of 3700 mg / L was also used, diluted 1 / 10 with binding buffer to provide a control. It was found that the IAC results were within the set limits required by the protocol. The supernatant samples were diluted 1 / 2 with binding buffer and then run on the column.
[0269] Example 2: Determining the appropriate concentration to determine the susceptibility of cell lines to different inhibitors
[0270] An initial evaluation was performed between two experiments using a model recombinant CHO antibody producing cell line (CHO149) to determine the appropriate concentration of each inhibitor for evaluation across the panel ( Figures 1A-1C and 2A-2F). A range of concentrations was analyzed based on those previously reported and used in the literature; 8 μM eeyarestatin has been previously shown in vivo to be sufficient to block ER translocation (Cross et al., 2009); 0.04-0.08 μM epoxomicin has been shown to inhibit the chymotrypsin activity of the proteasome (Meng et al., 1999); 1.5 μM MG-132 has been shown to induce apoptosis (Meriin et al., 1998).
[0271] Almost the same effect was observed after incubation of CHO149 cell line with 0.5 and 1 μM MG-132, with culture viability reduced to about 50% and viable cell number reduced by approximately 40% 48 hours after drug addition compared to control samples ( Figures 2A-2F MG-132 at a concentration of 0.1 μM had little effect on culture viability and cell number, whereas the effects produced by concentrations of 5 and 10 μM were severe, with both cell number and culture viability significantly reduced 48 hours after drug addition ( Figures 1A-1C and 2A-2F).
[0272] 0.5 and 1 μM concentrations of epoxomicin resulted in a 90% reduction in viable cell counts 48 hours after drug addition ( Figures 1A-1C ), while concentrations of 0.01, 0.005, and 0.001 μM resulted in an increase in the number of viable cells, and the drug did not show any deleterious effects until 72 hours after drug addition ( Figures 2A-2F By 48 hours after drug addition, 0.05 μM epoxomicin resulted in a 30-60% decrease in culture viability and a 30-50% decrease in viable cell number between the two experiments ( Figure 1A-Figure 1C and 2A-2F).
[0273] Addition of the inhibitor eeyarestatin I resulted in different effects between the two experiments, resulting in a reduction in viable cell numbers ranging from 15-30% 48 hours after addition at a concentration of 1 μM. The 10 μM concentration consistently showed an effect on culture viability parameters between the two experiments, although the magnitude of the effect was larger. Figures 1A-1C Based on the results in Figures 2A-2F, further studies determined that the concentrations were 0.5 μM for MG-132, 0.05 μM for epoxomicin, and 10 μM for eeyarestatin I. At these concentrations, a 30-60% reduction in the effects on cell concentration and culture viability was observed compared to control samples.
[0274] Example 3: Evaluation of ERAD and proteasome inhibitors across a panel of production cell lines
[0275] Using inhibitor concentrations as determined in Example 2, the effects of set concentrations of inhibitors were studied on a panel of CHO mAb-producing cell lines. All cell lines used were derived from the CHOK1SV host cell line and expressed model IgG4 molecules at different yields. The productivity of the cell lines had been previously determined, and these historical titers were used to select groups covering a range of productivity to determine susceptibility to inhibitors. Cells were then evaluated after the addition of inhibitors in a 96-deep well plate format, with daily cell counts performed after the addition of inhibitors.
[0276] After 48 hours of culture, culture viability and viable cell numbers varied between cell lines of different productivity. The maximum magnitude of the inhibitor effect was observed at 48 hours after addition, so this time point was used for correlation analysis.
[0277] The effect of the drug on cell line viability was compared to the productivity of the cells to determine if there was a strong correlation between productivity and susceptibility to the drug concentration being studied. Historical experimental production data of product concentration and specific production rate from fed-batch and bioreactor data were used to perform correlation analysis with inhibitor effects in a 96DWP format using linear regression and Pearson correlation analysis. A statistically significant correlation (p<0.05) was determined between cell line productivity and susceptibility to proteasome inhibitors.
[0278] After 48 h in the presence of 0.5 μM MG-132, a positive correlation was determined between viable cell concentration and specific production rate determined from fed-batch cultures, and between culture viability and specific production rate determined from fed-batch and bioreactor cultures ( Figures 3A-3Dand 6A-6G; and Table 4). When cells were cultured in the presence of 0.05 μM epoxomicin, there was again a positive correlation between viable cell number and specific production rate determined from both fed-batch and bioreactor cultures, and between viable cell number and product concentration determined from both fed-batch and bioreactor cultures ( Figures 4A-4D and 6A-6G; and Table 4). No statistically significant correlation was determined between culture viability and productivity data in the presence of 0.05 μM epoxomicin. There was also no significant correlation between cell culture parameters and productivity characteristics when cells were cultured in the presence of Eeyarestatin I.
[0279] Table 4: Summary of the effects of inhibitors on culture viability and viable cell concentration of CHO antibody producing cell lines with correlation coefficients to cell line productivity. (Shading indicates statistically significant correlations).
[0280]
[0281] Example 4: Determination of proteasome activity in production cell lines
[0282] As described in Example 3, the cell line groups studied showed differences in their susceptibility to proteasome inhibitors. Therefore, in order to further analyze this point, the level of proteasome activity was determined between the cell line groups. This was performed using proteasome activity spectrum analysis probes from the van der Hoorn laboratory (Kolodziejek et al., 2011). These probes have fluorescent tags and are designed based on inhibitor molecules with different active groups. Importantly, the probes can only bind to their targets when they are in an active state, so active proteasomes can be determined. The probes used in this study include MV151, which contains a vinyl sulfone reactive group and MVB003 and MVB072, both of which are based on the inhibitor molecule epoxomicin and have epoxyketone reactive groups. The reactive groups of these probes bind to the N-terminal active site Thr of the proteasome catalytic subunit through different mechanisms. These probes demonstrate the activity of the three catalytic subunits β1, β2 and β5 of the proteasome (Kolodziejek et al., 2011). In addition, probes RUB1001, which contain an epoxyketone reactive group and highlight β1 activity, and RUB1018, which have a vinylsulfone reactive group and highlight β5 catalytic subunit activity, were utilized. Analysis with activity probes allowed for the determination of proteasome activity between groups of cell lines as well as for the discovery of whether the activity of the various catalytic subunits of the proteasome differed between these studies.
[0283] Activity was determined by the fluorescence intensity of the various bands observed after labeling the samples as described in the Methods section. After determining the fluorescence levels, the gel was Coomassie stained to provide a loading control. Figures 7A-7FThe upper band of about 27 kDa observed in the β2 represents the catalytic activity. The lower band of about 24 kDa represents the catalytic activity of β5 and β1 ( Figures 7A-7F ), RUB1018 indicates only β5 activity. The MV151 probe indicates both β2 and β5 / β1 activity. Across cell line groups, the intensity of the lower β5 / β1 band was generally stronger than the β2 band ( Figures 7A-7F and 9A-9F), suggesting a higher activity of these subunits. However, when the MVB003 probe was used, there appeared to be a less intense β5 / β1 band and thus less activity in many antibody-producing cell lines compared to CHOK1SV ( Figures 7A-7F and 9A-9F). The β2 activity of the cell lines producing the recombinant antibodies was generally comparable to that observed in the CHOK1SV host cell line. As might be expected, when the MVB072 probe was utilized, a similar activity pattern to that of the MVB003 probe was observed ( Figures 7A-7F ), although minor changes in the β5 / β1 band were observed.
[0284] When the RUB1001 probe was used to study proteasome activity (which allows assessment of β5 and β1 activity individually), the catalytic activities of these two subunits mirrored each other across cell line panels ( Figures 8A-8F The level of proteasome activity as determined using the RUB1018 probe was found to be lower in many recombinant cell lines when compared to the CHOK1SV control ( Figures 8A-8F Fluorescence analysis was also performed without adding probe to the lysate samples and with epoxomicin inhibition before adding the probe to confirm that the banding pattern obtained was determined from binding of the probe to the catalytic subunit and not the result of nonspecific binding. This was confirmed by the absence of bands on the gel for these treated samples ( Figures 8A-8F )
[0285] The "total" activity determined for each probe was also investigated by analyzing the intensities of all bands observed with each probe in combination using densitometry. Thus, the total proteasome activity was derived from the sum of all intensities of all probes. Cell lines CHO142, CHO71, CHO77, CHO137, and CHO46 all showed elevated levels of total proteasome activity relative to the non-productive control CHOK1SV host ( Figures 9A-9F). All cell lines were originally derived from the CHOK1SV cell line, so this should provide a suitable baseline for proteasome activity without the pressure of recombinant protein production. Cell lines that showed an increase in total proteasome activity were generally intermediate to high in the range of productivity of those cell lines studied. However, other cell lines such as CHO149, CHO42, and CHO150 all showed a decrease in total proteasome activity compared to that observed in the host and are generally classified as high producers.
[0286] Example 5: Applying proteasome selection pressure to the cell line construction process
[0287] A correlation between cell line productivity and the susceptibility of the cell line to proteasome inhibitors has been observed (see Example 3). Therefore, the hypothesis that proteasome inhibitors can be used to select high-producing recombinant cell lines during cell line construction was investigated. Therefore, a cell line construction process was designed to generate a CHOK1 GS-KO recombinant cell line producing model antibody A, which included the addition of a proteasome inhibitor as an additional selection pressure to methionine sulfoximine (MSX). Fig.10 The cell line construction process design is outlined in . MSX is used to select cells that successfully express the transfected plasmid by selecting for glutamine synthase (GS) expression. Although CHO cells endogenously express small amounts of GS, MSX can be used as an inhibitor to select for cells in which the construct containing GS has been stably incorporated into the genome (Fan et al., 2012). In addition, the host used in this example is a CHOK1 GS-KO host cell line that lacks any endogenous GS protein expression. Proteasome inhibitors were added in addition to typical selections to test whether including selection based on proteasome inhibition selects for cell populations that are high producers of antibody products. The data presented in Example 3 suggest that those cells with higher productivity are less susceptible to proteasome inhibitors and should therefore be selected in the presence of inhibitors. To test this hypothesis, an experimental approach was designed to determine those inhibitor concentrations to be studied using a range of combinations of MSX and proteasome inhibitor concentrations on the CHOK1 GS-KO host cell line transfected with a plasmid encoding antibody A. These were Fig.10 Proteasome inhibitors were added 24, 96, or 168 hours after the addition of MSX to allow selection based on plasmid uptake to occur prior to inhibition of the proteasome.
[0288] For the purposes of the cell line establishment process, the concentration of MG-132 used was lower than that used to generate the data reported in Example 2. The concentration previously studied in the data reported in Example 2 resulted in poor viable cell counts after electroporation and the cell line establishment process. Therefore, the concentration used for the cell line establishment evaluation was reduced.
[0289] Eight of the 30 cell line construction processes evaluated survived the cell line construction process. These were four controls treated with different MSX concentrations alone (i.e. no proteasome inhibitors were added) and four where the process contained either MG-132 or epoxomicin along with the inclusion of MSX. These cell populations were cultured and expanded until they were grown in suspension batch cultures to assess growth and antibody concentrations from these cell populations. For this purpose, 0.2 x 10 6 Cells were seeded at a concentration of 10 cells / ml and incubated at 37°C in a Kuhner incubator with shaking at 140 rpm, and samples were taken every 48-72 hours to determine cell concentration and culture viability on a ViCell instrument. In general, growth characteristics were similar between all cell populations, such as Fig.11 CLC18 (this cell line construction was performed in the presence of 0.025 μM epoxomicin and 37.5 μM SMSX) had a slower growth rate than the other cultures and did not reach such high viable cell numbers, which were 8-10 x 10 in the other cell line construction populations. 6 cells / ml compared to 5.328 x 10 6 CLC6 and CLC27 cell line constructs generated in the presence of MSX alone dropped in culture viability at earlier time points compared to the other populations, with viabilities of 5.8% and 24.2%, respectively, at 192 hours in culture.
[0290] When analyzing the antibody concentration in the supernatant of different cell pools, there was a large difference in product concentration between the different cell lines when constructs were made with or without protein degradation inhibitors. Antibody concentrations were determined from supernatants collected at 192 hours of batch culture and analyzed by ELISA ( Fig.12 ) and protein A HPLC assay. The results obtained from protein A HPLC were similar to those observed by ELISA assay. All cultures prepared with the additional selection pressure of proteasome inhibitors on top of the usual MSX selection showed an increase in antibody concentration relative to that observed from the pools produced by MSX alone. In fact, those pools produced with 0.0625 μM MG-132 and 37.5 μM MSX showed an approximately 4-fold increase in the amount of antibody present in the cell culture supernatant, while those produced with 0.025 μM epoxomicin and 37.5 μM MSX showed a 3-7-fold increase in antibody concentration relative to different control pools produced with MSX alone. Therefore, these data indicate that the use of proteasome inhibitors together with MSX selection results in cell pools that produce higher model recombinant monoclonal antibody yields.
[0291] The susceptibility of recombinant CHO cell lines expressing a model monoclonal antibody to the proteasome inhibitors MG-132 and epoxomicin was found to differ among a panel of industrially relevant model antibody producing GS-CHO recombinant cell lines (as described in Example 2). A positive correlation was found between culture viability or viable cell number and productivity when the cells were cultured in the presence of the studied concentrations of proteasome inhibitors.
[0292] The data disclosed herein demonstrate that the proteasome in the high-yield cell line is less affected by the inhibitory effect, indicating that fewer polypeptides or proteins need to be degraded, possibly due to the presence of less misfolded proteins and thus leading to higher yields. High-yield cell lines have previously been associated with increased amounts of chaperones in mammalian cell lines expressing recombinant proteins, so the fidelity of folding can be improved in these cells, thereby making them better promote high-level recombinant protein production (Smales et al. 2004; Dinnis et al., 2006), potentially via activation of the UPR due to ER stress.
[0293] Due to the positive correlation between proteasome inhibition and antibody productivity observed in Example 3, it was hypothesized that the effect of proteasome inhibition could be used to select for higher recombinant protein producing populations during cell line construction. MSX is currently one of the main selection systems used to inhibit endogenous glutamine synthase (GS) of CHO cells and select for cells expressing exogenous GS on the introduced recombinant plasmid, resulting in a heterogeneous population with different recombinant protein expression levels. Figures 6A-6G Based on the correlation data reported in , it was investigated whether the addition of proteasome inhibitors as well as MSX would promote the emergence and selection of heterogeneous cell populations with enhanced productivity and potentially product quality. Therefore, when transfected with a model antibody A plasmid containing the GS gene and the heavy and light chains of the model IgG4 antibody A, epoxomicin and MG-132 were added to the cell line construction process of the GSKO cell line. When applied to the selection process of transfection, most combinations of MSX and epoxomicin and MG-132 concentrations could not survive the selection process and subsequent culture. Cell viability of <6% was achieved in the cultures from this experiment, except for 8 cultures that were carried out to the end of the experiments described herein. However, when analyzed by ELISA or protein A HPLC, those populations that did appear in the presence of 0.0625 μM MG-132 or 0.025 μM epoxomicin and 37.5 μM MSX produced higher amounts of cB72.3 antibodies after 192 hours of batch culture when compared to those populations cultured with MSX alone. Therefore, the additional selection pressure does appear to select for higher production populations, consistent with previously reported correlation data. This data has potential benefits for use in cell line construction processes in an industrial setting to aid in the development of higher production GS-CHO recombinant cell populations.
[0294] Example 6. Use of proteasome and ERAD inhibitors in cell line construction
[0295] In 1x10 7 Multiple electroporations were performed with 20 μg of linearized construct containing GS cB72.3 monoclonal antibody in each live GS KO Lonza host cell and pooled. This pool was then set up as 10 ml cultures, each containing approximately 0.25 x 10 6 Cells and 10 μg DNA were added and immediately placed in a static incubator at 37°C, 5% CO2. The cell culture medium consisted of commercial CD-CHO medium without glutamine and with the addition of MSX and inhibitors as outlined below. 24 hours after transfection, MSX was added to the culture medium to bring the culture volume to 15 ml and provide a final MSX concentration of 37.5 μM. The different inhibitors were then added to the pool 24 hours after the addition of MSX. Fig.13 Each inhibitor was added to a range of concentrations to give a final concentration in the flask as described in . Each flask received only one inhibitor treatment (no combination treatments) and was combined with 37.5 μM MSX as described in Fig.13 Overview.
[0296] The cell pool was then placed in a static incubator at 37°C and 5% CO2 until the viable cell concentration in the flask reached approximately 0.2 x 10 6 cells / ml. When this viable cell count was reached, the cell pool was moved into a 125 mL Erlenmeyer shake flask and cultured in a 20 mL volume of CD-CHO containing MSX and the appropriate concentration of inhibitor at 37°C under 5% CO2 in an air environment with shaking at 140 rpm. Finally, 24 of the 33 transfections / pools were moved to a shake flask because they exceeded the required viable cell concentration described above. The final inhibitor concentrations that led to the appearance of cell pools together with 37.5 μM MSX were as follows: MG-132: 15.625 and 31.25 nM; Epoxymycin: 6.25, 12.5 and 25 nM; Eeyarestatin I: 0.1, 0.5 and 1 μM concentrations.
[0297] The cell pool was then cultured for several generations (0.2 x 10 6 viable cells / ml inoculum), and then batch cultures were set up for each time to assess the growth of the pool and sampled for product concentration during the culture. For this purpose, 20 ml of batch cultures were sampled at 48, 96 and 168 hours (at 0.2×10 6The cell pool was then passaged two more times in the absence of inhibitor (but with MSX) to determine if any changes in growth or productivity were observed, i.e., improved culture titers were only maintained if the inhibitor was continuously present. The findings and data are presented in Figure 13-18 Presented in.
[0298] First, the average mAb product concentrations achieved following the recombinant GS-CHO cell line construction process with various inhibitors were evaluated from batch cultures set up from cells cultured continuously in the presence of the inhibitors ( Fig.14 The cB72.3 mAb concentration was assessed from supernatant samples at 0.2×10 of a cell pool generated from a cell line constructed with a proteasome inhibitor in addition to the MSX selection pressure. 6 20 mL batch cultures were harvested at 48, 66 and 168 hours after inoculation with 10 viable cells / ml. Product titers were assessed using a protein A sensor on the Octet system (n=3 for 37.5 μM MSX control, n=2 for inhibitor treatments, except for 25 nM epoxomicin n=1). Fig.14 As shown, the cell pool constructed in the presence of 31.25 nM MG-132 and 37.5 μM MSX exhibited enhanced mAb titers that were almost 4-fold higher than those observed from the control pool after 168 h of batch culture.
[0299] Second, analysis of monoclonal antibody products achieved after the recombinant GS-CHO cell line construction process with various inhibitors was performed by western blotting from batch cultures set up with cells cultured continuously in the presence of inhibitors ( Fig.15 ). The cB72.3 concentration was determined from supernatant samples at 0.2×10 of a cell pool generated from a cell line constructed with a proteasome inhibitor in addition to the MSX selection pressure. 6 The cells were harvested 168 hours after inoculation with viable cells / ml. Western blots were probed with an anti-heavy chain antibody (Sigma). Fig.15 As shown, cell pools produced in the presence of different inhibitors generally showed more intense antibody bands than cell pools from control, MSX alone production, and thus higher antibody productivity.
[0300] Third, the average mAb product concentrations achieved following the recombinant GS-CHO cell line construction process with various inhibitors were evaluated from batch cultures set up from cells grown for two generations in the absence of inhibitors ( Fig.16The cB72.3 mAb concentration was assessed from supernatant samples at 0.2×10 of a cell pool generated from a cell line constructed with a proteasome inhibitor in addition to the MSX selection pressure. 6 20 mL batch cultures were harvested at 48, 96 and 168 hours after inoculation with 10 viable cells / ml. Product titers were assessed using a protein A sensor on the Octet system (n=3 for 37.5 μM MSX control, n=2 for inhibitor treatments, except for 25 nM epoxomicin n=1). Fig.16 As shown, the cell pool constructed in the presence of 31.25 nM MG-132 and 37.5 μM MSX exhibited enhanced mAb titers that were almost 4-fold higher than those observed from the control pool after 168 h of batch culture.
[0301] Fourth, analysis of monoclonal antibody products after the recombinant GS-CHO cell line construction process with various inhibitors via western blot assay from batch cultures set up from cells cultured for two generations in the absence of inhibitors ( Fig.17 ). cB72.3 concentrations were assessed from supernatant samples at 0.2×10 of cell pools generated from cell line construction with proteasome inhibitors in addition to MSX selection pressure. 6 The cells were harvested at 168 h post-inoculation with 10 viable cells / ml. The cell pool was passaged twice in the absence of inhibitors before sampling batch cultures. Western blots were probed with an anti-heavy chain antibody (Sigma). Fig.17 As shown, cell pools produced in the presence of different inhibitors generally displayed more intense antibody bands than cell pools from control, MSX alone production, and therefore higher antibody productivity.
[0302] Fifth, the average specific productivity ( Fig.18 Specific productivity was calculated from data collected on viable cell number (determined on Vicell) and product concentration (derived using a protein A probe on the octet system) from supernatant samples of 0.2×10 of a cell pool generated from a cell line constructed with a proteasome inhibitor in addition to MSX selection pressure. 6 The viable cells / ml were collected at 48, 96 and 168 hours post-inoculation. The individual specific activity of each cell pool was calculated and then the mean value of each treatment was determined (n=3 for 37.5 μM MSX control, n=2 for inhibitor treatments, except for 25 nM epoxomicin n=1). Fig.18As shown, when cell pools were generated in the presence of MG-132, particularly at a concentration of 31.25 nM, and various concentrations of epoxomicin and eeyarestatin, the cell specific productivity was enhanced compared to the MSX control pool.
[0303] Sixth, the calculated average cellular monoclonal antibody specific productivity ( ) achieved after the recombinant GS-CHO cell line construction process with various inhibitors was evaluated from batch cultures set up from cells cultured for two generations in the absence of inhibitors. Fig.19 Specific productivity was calculated from cell number (determined on Vicell) and product concentration (derived using a protein A probe on the octet system) determined from supernatant samples of 0.2×10 of a cell pool generated from a cell line constructed with a proteasome inhibitor in addition to MSX selection pressure. 6 The viable cells / ml were inoculated and collected at 48, 96 and 168 hours after batch culture. The individual specific activity of each cell pool was calculated and then the average of each treatment was determined (n=3 for 37.5 μM MSX control, n=2 for inhibitor treatment, except for 25 nM epoxomicin n=1). Fig.19 As shown, when cell pools were generated in the presence of MG-132, particularly at a concentration of 31.25 nM, and various concentrations of epoxomicin and eeyarestatin, cell specific productivity was enhanced compared to the MSX control pool.
[0304] in conclusion
[0305] Overall, Figure 14-19 The data described in demonstrate that cell pools with increased selective pressure from proteasome and ERAD inhibitors can produce cell pools with enhanced productivity over equivalent controls selected with MSX alone. This provides further evidence that the addition of proteasome or ERAD inhibitors to the cell line construction process provides additional selective pressure, leading to the emergence of culture populations with improved specific productivity and excess recombinant product substrate.
[0306] Example 7. Stabilization of recombinant CHO cell pools produced with inhibitors used during the cell line construction process sex
[0307] Cell pools from previous cell line constructions generated using the GS selection system in the presence of proteasome inhibitors and MSX as additional selective pressure were recovered after cryopreservation. These pools were then passaged 15 times every 3-4 days to determine whether the beneficial effects of the additional selective pressure were maintained over time. Routine subcultures were performed every 3-4 days and samples were taken from later passages to determine whether the effect on product yield was maintained over time. In each passage, 20 ml CD-CHO and MSX as outlined below were cultured in 125 ml Erlenmeyer shake flasks at 37°C under 5% CO2 in an air environment with shaking at 140 rpm (using 0.2 x 10 6 Batch cultures of recombinant cell pools expressing model monoclonal antibodies were set up at 4% viable cells / mL. Fig.23 As shown, the relative cell specific productivity between different cell pools was preserved over different passage numbers.
[0308] Example 8. Selection / Adaptation of GS-KO by Culture in the Presence of Proteasome or ERAD Inhibitors CHO cell hosts to generate new hosts with enhanced productivity characteristics.
[0309] To determine whether adapted / selected host cells with the ability to produce enhanced recombinant protein yield and quality can be generated by culturing the Lonza GS-KO CHO host cell line in the presence of protein degradation inhibitors, GS-KO host cells were cultured for a series of passages in the presence of various protein degradation inhibitors. Thus, the host cell line was cultured in 20 ml CD-CHO + 6 mM glutamine + appropriate inhibitors as outlined below in 125 ml Erlenmeyer shake flasks at 37°C in 5% CO2 in an air environment with shaking at 140 rpm. At each passage, a new culture was plated at 0.2 x 10 6 When the cell count exceeds 1x 10 per mL 6 Subculture cells when 1 viable cell is present.
[0310] The following concentrations and passages were used: host cells were treated with DMSO, or with MG132 at a final concentration of 15.6 nM, Eeyarestatin I at a final concentration of 1 and 0.1 μM, and epoxomicin at a final concentration of 6.25 nM, and 9 passages were performed after the addition of the drug to the host. The host cells in the final MG132 concentration of 62.5 nM were passaged 5 times after the addition of the drug, and the host cells in the epoxomicin at a final concentration of 25 nM were passaged 8 times after the addition of the drug. Then, all of the above cells had 2 more passages in the absence of the drug to perform transient expression experiments, thereby removing the selection / adaptation pressure. In the case of host cells cultured in the presence of a final concentration of 125 nM MG132, there were not enough cells for the first experiment, in which the transfection of the vector containing the model monoclonal antibody was performed immediately after the culture in the presence of the drug. However, the cells in the presence of this concentration of MG132 were passaged 4 times at this concentration, and then 2 more passages were performed in the absence of the drug. At this point, there were enough cells for transfection to be performed after passaging the cells in the absence of drug (the second experiment of two).
[0311] Then, the cells were cultured by adding 20 μg of the model cB72.3 plasmid and 1 x 10 7 Transient transfection of the host cell pool described above was performed by electroporation of live cells and the cells were placed in 125 ml Erlenmeyer shake flasks with 20 ml fresh CD-CHO medium plus 6 mM glutamine and cultured at 37°C in an air environment with shaking at 140 rpm under 5% CO2. This was done for host cell pools that had been continuously cultured in the presence of inhibitors and for those that had been passaged for 2 more generations in the absence of inhibitors. Samples were taken from these batch cultures to monitor growth and antibody titers at 48, 96 and 168 hours post-transfection. Figure 20-23 The results and data are presented in.
[0312] First, we evaluated the antibody product concentrations achieved after transient transfection in batch cultures of host cell pools following incubation in the presence of proteasome or ERAD inhibitors ( Fig. 20 ). 20 μg DNA was electroporated into 1x10 7 cB72.3 concentrations were assessed in supernatant samples taken 48, 96, and 168 hours post-transfection after viable cells were added and resuspended in 20 ml culture. Host cell lines were cultured in the presence of indicated proteasome and ERAD inhibitors at indicated concentrations prior to electroporation. Product titers were assessed using a protein A sensor on the Octet system. Fig. 20As shown, cells cultured in the presence of 0.1 μM final concentration of Eeyarestatin I produced higher transient titers than DMSO control cells, providing evidence that culturing host cells in the presence of proteasome inhibitors can be used to adapt / select cells with higher recombinant protein production capacity.
[0313] Second, we evaluated the antibody product concentrations achieved after initial culture in the presence of proteasome or ERAD inhibitors, followed by subsequent subculture in the absence of inhibitors for 2 generations, followed by transient batch culture followed by transient transfection of CHO host cell pools ( Fig.21 ). 20 μg DNA was electroporated into 1x10 7 cB72.3 concentrations were assessed in supernatant samples taken 48, 96, and 168 hours after transfection after viable cells were added and resuspended in 20 ml batch cultures. Host cell lines were initially cultured in the presence of proteasome and ERAD inhibitors prior to electroporation and then passaged twice in the absence of inhibitors. Product titers were assessed using a protein A sensor on the Octet system. Fig.21 As shown, cells initially cultured in the presence of Eeyarestatin I or 6.25 nM epoxomicin produced higher transient titers than DMSO control cells, providing evidence that culturing host cells in the presence of proteasome inhibitors can be used to adapt / select cells with higher recombinant protein production capacity.
[0314] Third, antibodies were assessed by western blot in supernatants of batch cultures following transient transfection of host cell pools either immediately after culture in the presence of proteasome or ERAD inhibitors or after two passages of subculture in the absence of inhibitors ( Fig. 22 ). 20 μg DNA was electroporated into 1x10 7 cB72.3 concentrations were assessed in supernatant samples taken 168 hours after transfection after 4 live cells were added and resuspended in 20 ml batch cultures. Host cell lines were initially cultured in the presence of proteasome and ERAD inhibitors prior to electroporation and then passaged twice in the absence of inhibitors. Western blots were probed with an anti-heavy chain antibody (Sigma). Fig. 22 As shown, various combinations of protein degradation inhibitors produced stronger antibody bands than DMSO control cells, providing evidence that culturing host cells in the presence of proteasome inhibitors can be used to adapt / select cells with higher recombinant protein production capacity.
[0315] in conclusion
[0316] The effect of the presence of proteasome or ERAD inhibitors during the culture of host cell colonies before transfection is particularly shown to increase cell specific productivity and titer when adding low concentrations of Eeyarestatin I (0.1 μM) to the culture medium for cell selection / adaptation. This suggests that the selection / adaptation of CHO host cell lines in the presence of protein degradation inhibitors can be used to produce host colonies with enhanced ability to produce recombinant proteins. However, in order for proteasome or ERAD inhibitors to be selected most effectively, it is necessary to produce the demand for recombinant products. In order for the colony to appear with a stable phenotype (e.g., enhanced product titer and quality), the host can be cultured for a longer period of time and a higher number of generations.
[0317] 1. A method for evaluating, classifying, identifying, generating or selecting a cell or progeny cell or a population of progeny cells, e.g., for producing a product, e.g., a polypeptide, a recombinant polypeptide, the method comprising:
[0318] a) optionally providing cells;
[0319] b) contacting the cell (or a descendant of the cell) with a protein degradation inhibitor, such as a proteasome inhibitor, a ubiquitin pathway inhibitor, or an endoplasmic reticulum-associated degradation (ERAD) inhibitor;
[0320] c) evaluating the effect of a protein degradation inhibitor, such as a proteasome inhibitor, a ubiquitin pathway inhibitor or an ERAD inhibitor, on one or more parameters associated with cellular function in said cell (or a progeny of said cell);
[0321] d) optionally comparing the value of the effect of a protein degradation inhibitor, such as a proteasome inhibitor, on said one or more parameters with a reference value; and
[0322] e) optionally expressing a product, such as a recombinant polypeptide, from the cell (or progeny of the cell); and
[0323] Thereby evaluating, classifying, identifying, generating or selecting a cell or a progeny cell or a population of progeny cells.
[0324] 2. The method of item 1, further comprising, for example as part of step (b), culturing the cells (or progeny of the cells) contacted with the protein degradation inhibitor, for example to provide a cultured cell population, for example a progeny cell population.
[0325] 3. The method of claim 1 or 2, comprising comparing the value of the effect of the protein degradation inhibitor, such as a proteasome inhibitor, to a reference value, such as wherein when the value meets or exceeds the reference value, identifying, classifying or selecting cells or progeny cells or a population of progeny cells, such as for establishing a culture, such as a cell pool or for producing a product, such as a polypeptide, such as a recombinant polypeptide.
[0326] 4. The method of any one of items 1-3, further comprising establishing a cell line from the cell or progeny cell.
[0327] 5. The method of any one of items 1 to 4, wherein the parameter associated with cell function comprises a member selected from the group consisting of:
[0328] i) cell survival,
[0329] ii) Cultivate viability,
[0330] iii) the ability to produce a product, such as a polypeptide, such as a recombinant polypeptide,
[0331] iv) proteasome activity; or
[0332] v) The quality of the expression product, e.g., a polypeptide, e.g., a recombinant polypeptide, e.g., a more homogeneous product.
[0333] 6. The method of any one of items 1-5, wherein the protein degradation inhibitor is a proteasome inhibitor, optionally wherein the proteasome inhibitor inhibits or reduces the activity of one or more of the following: 20S core subunit, 19S regulatory subunit, 11S regulatory particle, or a chaperone protein that assists in proteasome assembly, such as Hsm3 / S5b, Nas2 / p27, Rpn14 / PAAF1 and Nas6 / gankyrin, optionally wherein the proteasome inhibitor is selected from MG132, epoxomicin, bortezomib, ixazomib, carfilzomib, disulfiram, CEP-18770, ONX 0912, salinosporamide, LLnV, CEP1612, lactacystin, PS-341, and eponomicin.
[0334] 7. The method of any one of items 1-5, wherein the protein degradation inhibitor is an ERAD inhibitor, optionally wherein the ERAD inhibitor inhibits or reduces the activity of one or more of the following: calnexin / calreticulin, UDP-glucose-glycoprotein glucosyltransferase, ER degradation-enhancing α-mannosidase-like protein (EDEM), ER mannosidase I, Sec61, CDC48p (VCP / p97), Hrd1, Doa10, Ubc6, Ubc1, Cue1, or Ubc7, optionally wherein the protein degradation inhibitor is eeyarestatin I.
[0335] 8. The method of any one of items 1-5, wherein the protein degradation inhibitor is a ubiquitin pathway inhibitor, optionally wherein the ubiquitin pathway inhibitor inhibits or reduces the activity of one or more of the following: an E1 ubiquitin activating enzyme, an E2 ubiquitin conjugating enzyme, or an E3 ubiquitin ligase.
[0336] 9. The method of any one of items 6 to 8, further comprising:
[0337] The cell is contacted with a second inhibitor of protein degradation, such as a proteasome inhibitor, an ERAD inhibitor, or an ubiquitin pathway inhibitor, optionally wherein the cell is contacted with a first and a second inhibitor of protein degradation, such as simultaneously or sequentially.
[0338] 10. The method of claim 9, wherein:
[0339] (i) the first protein degradation inhibitor and the second protein degradation inhibitor are selected from MG132, epoxomicin or eeyarestatin 1;
[0340] (ii) the first inhibitor is a proteasome inhibitor, and the second inhibitor is a proteasome inhibitor;
[0341] (iii) the first inhibitor is a proteasome inhibitor, and the second inhibitor is an ERAD inhibitor or a ubiquitin pathway inhibitor;
[0342] (iv) the first inhibitor is an ERAD inhibitor, and the second inhibitor is an ERAD inhibitor;
[0343] (v) the first inhibitor is an ERAD inhibitor, and the second inhibitor is a ubiquitin pathway inhibitor or a proteasome inhibitor;
[0344] (vi) the first inhibitor is a ubiquitin pathway inhibitor and the second inhibitor is a ubiquitin pathway inhibitor; or
[0345] (vii) the first inhibitor is a ubiquitin pathway inhibitor, and the second inhibitor is an ERAD inhibitor or a proteasome inhibitor.
[0346] 11. The method of any one of items 1-10, wherein the cells are contacted with a concentration of the protein degradation inhibitor sufficient to reduce the viability of the culture by about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or 75%, for example, compared to the viability of the culture before contacting the culture with the inhibitor, or compared to a culture not contacted with the inhibitor, optionally wherein the concentration of the protein degradation inhibitor is a concentration at which one or more cells continue to proliferate.
[0347] 12. The method of any one of items 1 to 11, wherein the concentration of the protein degradation inhibitor is less than 0.5 μM MG-132, such as about 0.0625 μM MG-132; or less than 0.05 μM epoxomicin, such as about 0.025 μM epoxomicin.
[0348] 13. The method of any one of items 1 to 12, wherein the cells are contacted with the protein degradation inhibitor, for example, the cells are cultured in the protein degradation inhibitor for 24, 48, 72, 96 hours or more.
[0349] 14. The method of any one of items 1 to 13, wherein the cells are contacted with the protein degradation inhibitor before, 24, 48, 72, 96, or 168 hours after, or simultaneously or in parallel with a selection step, such as MSX selection.
[0350] 15. The method of any one of items 1 to 14, comprising:
[0351] A cell expressing the product, e.g., the polypeptide, e.g., the recombinant polypeptide, is provided, e.g., a cell comprising an exogenous nucleic acid encoding the polypeptide, e.g., the recombinant polypeptide, or controlling expression of the polypeptide, e.g., the recombinant polypeptide.
[0352] 16. The method of claim 15, wherein the product comprises a recombinant polypeptide, such as an antibody molecule (e.g., a monoclonal antibody), a bispecific molecule, a coagulation factor, an anticoagulant, a hormone, an interferon, an interleukin, or an enzyme, for example, selected from Table 1 or 2.
[0353] 17. The method of any one of items 1-16, wherein the cell is a eukaryotic cell, such as a mammalian cell.
[0354] 18. The method of any one of items 1-17, wherein the cell is from a mouse, rat, Chinese hamster, Syrian hamster, monkey, ape, human, dog, camel, horse, ferret or cat; or is a eukaryotic cell other than a mammalian cell, for example, the cell is from an insect, plant, duck, parrot, fish or yeast.
[0355] 19. The method of any one of items 1-18, wherein the cell is a CHO cell, such as CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, CHOZN, or a CHO-derived cell.
[0356] 20. The method of any one of items 1-18, wherein the cells are selected from HeIa, HEK293, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK, VERO, SP2 / 0, NS0, YB2 / 0, EB66, C127, L cells, COS, such as COS1 and COS7, QC1-3, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, and CHOZN.
[0357] 21. The method of any one of items 1 to 20, which comprises expressing the product, e.g., the polypeptide, e.g., the recombinant polypeptide, from the cell or progeny cell, and optionally, wherein the expressed product, e.g., the polypeptide, e.g., the recombinant polypeptide, is evaluated for parameters associated with a physical or functional property, e.g., primary sequence, glycosylation, primary, secondary, tertiary or quaternary structure, activity, degree of glycosylation, degree of aggregation, the proportion or level of expression products having a preselected property, e.g., a preselected monomer, dimer or trimer structure, or the level or proportion of expression products having a preselected structure, e.g., a non-denatured or non-aggregated structure.
[0358] 22. The method of any one of items 1-21, further comprising introducing an exogenous nucleic acid into the cell, optionally wherein the exogenous nucleic acid is introduced before or after one or more of steps a), b), c) and d).
[0359] 23. The method of claim 22, wherein the exogenous nucleic acid encodes a polypeptide, such as a recombinant polypeptide, such as a therapeutic polypeptide or an antibody molecule selected from Table 1 or 2.
[0360] 24. The method of items 1-23, further comprising introducing one or more additional exogenous nucleic acids, such as a second exogenous nucleic acid, into the cells, optionally wherein the introduction of the exogenous nucleic acid comprises transfection, electroporation or transduction, optionally wherein the second exogenous nucleic acid is introduced before or after one or more of steps a), b), c) and d).
[0361] 25. The method of items 22-24, wherein the second exogenous nucleic acid is introduced before, after or simultaneously with the introduction of the first exogenous nucleic acid, optionally wherein the second exogenous nucleic acid encodes a selection marker, such as glutamine synthase.
[0362] 26. The method of items 1-25, which also includes evaluating a second characteristic of the cell, for example, determining whether the cell contains an exogenous component, such as one or more exogenous nucleic acids, such as one or more exogenous nucleic acids integrated into the nucleic acid of the cell, such as one or more exogenous nucleic acids integrated into the chromosomal genome of the cell, optionally wherein determining whether the cell contains one or more exogenous nucleic acids integrated into the nucleic acid of the cell, such as one or more exogenous nucleic acids integrated into the chromosomal genome of the cell comprises MSX selection, MTX selection (e.g., DHFR system), antibiotic selection, yeast growth selection, selection based on color change or surface expression of a marker, selection based on the Selexis system, or selection based on the Catalant system, optionally wherein antibiotic selection comprises selecting for resistance to an antibiotic selected from hygromycin, neomycin (G418), zeocin, puromycin or blasticidin.
[0363] 27. The method of any one of items 1 to 26, wherein the cell comprises an exogenous nucleic acid encoding the product, such as the recombinant polypeptide, or an exogenous nucleic acid controlling the expression of the product, such as an endogenous polypeptide.
[0364] 28. The method of any one of items 22-27, wherein the exogenous nucleic acid further comprises a nucleic acid sequence encoding a selection marker, optionally wherein the selection marker comprises glutamine synthase, DHFR, or a gene conferring antibiotic resistance.
[0365] 29. The method of claim 28, wherein the nucleic acid sequence encoding the selection marker is operably linked to a first promoter, and the nucleic acid sequence encoding the polypeptide, e.g., the recombinant polypeptide, is operably linked to a second promoter, optionally wherein the first promoter and the second promoter are different.
[0366] 30. The method of claim 29, wherein:
[0367] (i) the promoter operably linked to the selectable marker is a weak promoter, such as the SV40E promoter; and / or
[0368] (ii) The promoter operably linked to the nucleic acid sequence encoding the polypeptide, such as a recombinant polypeptide, is a strong promoter, such as a CMV promoter, such as an hCMV-MIE promoter.
[0369] 31. The method of any one of items 1-30, wherein the product, such as a polypeptide, such as a recombinant polypeptide, has the same amino acid sequence that differs from a naturally occurring isoform of a human polypeptide at no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues, for example wherein the product, such as a polypeptide, such as a recombinant polypeptide is a polypeptide from Table 1 or Table 2.
[0370] 32. The method of any one of items 1 to 31, comprising:
[0371] c) evaluating the effect of the protein degradation inhibitor, e.g., a proteasome inhibitor, on a parameter associated with cell function, e.g., survival, viability, or proliferation capacity, or the ability to produce a product, e.g., a polypeptide, e.g., a polypeptide expressed from an exogenous nucleic acid; and
[0372] d) determining, by e.g. MSX selection, whether the cell comprises the exogenous nucleic acid integrated into the chromosomal genome of the cell.
[0373] 33. The method of any one of items 1-32, wherein the value of the effect of the protein degradation inhibitor, such as a proteasome inhibitor, on the parameter associated with cell function exceeds a reference value by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times or 8 times or more, wherein the reference value is the value of the effect of the protein degradation inhibitor on the parameter associated with the cell function of a reference cell or the value of the effect on the parameter associated with the cell function of a cell that has not yet been contacted with the protein degradation inhibitor.
[0374] 34. The method of claim 33, wherein the parameters include one or more of the following:
[0375] (i) the ability to produce a product, such as a polypeptide, such as a recombinant polypeptide, such as a recombinant polypeptide expressed from an exogenous nucleic acid;
[0376] (ii) the ability to produce a product, such as a polypeptide, such as a recombinant polypeptide, and wherein the increase is determined by measuring or quantifying the product, such as the polypeptide, such as the recombinant polypeptide, in or secreted by the cell;
[0377] (iii) cell survival, and wherein the increase or decrease is determined by measuring or quantifying the number of apoptotic cells; or
[0378] (iv) culture viability, and wherein the increase or decrease is determined by measuring or quantifying the number of viable cells.
[0379] 35. The method of any one of items 1-34, further comprising an additional selection step, such as selection by FACS, magnetic separation (e.g., using magnetic beads), colony picking, microfluidic cell sorting, or microfluidic cell disruption.
[0380] 36. The method of any one of items 1-35, which also includes introducing into the cell an agent that assists protein folding, such as a chaperone molecule or a small chemical molecule, optionally wherein the agent that assists protein folding comprises a nucleic acid encoding a chaperone protein or a component of a protein folding pathway, such as XBP1, SRP14, BiP / GRP78, PDI, calnexin or cyclophilin B; or a small molecule selected from DMSO, glycerol or PBA.
[0381] 37. A method for generating a cell line or a cell population, comprising:
[0382] a) identifying or selecting a cell by the method of any one of items 1-36; and
[0383] b) culturing the cell or cell population to provide a cell line or cell population.
[0384] 38. The method of claim 37, wherein said identifying or selecting cells comprises contacting said cells or cell populations with a protein degradation inhibitor, such as a protein degradation inhibitor according to claims 6-12.
[0385] 39. The method of item 37 or 38, which further comprises introducing into the cell an exogenous nucleic acid encoding a product, such as a recombinant polypeptide, or controlling, such as increasing, the expression of a product, such as an endogenous polypeptide.
[0386] 40. The method of any one of items 37-39, which comprises expressing the product, e.g., the polypeptide, e.g., the recombinant polypeptide, from the cell or progeny cell, and optionally, wherein the expressed product, e.g., the polypeptide, e.g., the recombinant polypeptide, is evaluated for parameters related to physical or functional properties, such as primary sequence, glycosylation, primary, secondary, tertiary or quaternary structure, activity, degree of glycosylation, degree of aggregation, the proportion or level of expression products having a preselected property, such as a preselected monomer, dimer or trimer structure, or the level or proportion of expression products having a preselected structure, such as a non-denatured or non-aggregated structure.
[0387] 41. The method of any one of items 37 to 40, wherein the identifying or selecting a cell further comprises performing a selection step, e.g., a step for determining whether the cell comprises one or more exogenous nucleic acids, optionally wherein the selection step comprises:
[0388] (i) determining whether the cell comprises one or more exogenous nucleic acids integrated into the nucleic acid of the cell, such as one or more exogenous nucleic acids integrated into the chromosomal genome of the cell; or
[0389] (ii) MSX selection, MTX selection, antibiotic selection, yeast growth selection, selection based on color change or surface expression of a marker, selection based on the Selexis system, or selection based on the Catalant system.
[0390] 42. The method of any one of items 37-41, further comprising establishing a cell line from the cell.
[0391] 43. The method of any one of items 37-42, wherein the product comprises a polypeptide, such as a recombinant polypeptide, such as an antibody molecule (e.g., a monoclonal antibody), a bispecific antibody), a coagulation factor, an anticoagulant, a hormone, an interferon, an interleukin or an enzyme, for example, a polypeptide having the same amino acid sequence or differing from a polypeptide from Table 1 or Table 2 by no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues.
[0392] 44. The method of any one of items 37-43, wherein the cell is a eukaryotic cell, such as a cell according to any one of items 17-20.
[0393] 45. A method of producing a product, such as a polypeptide, such as a recombinant polypeptide, comprising:
[0394] a) providing a cell or cell population produced by the method of any one of items 37-44;
[0395] b) culturing the cell or cell population in a culture medium; and
[0396] c) optionally, recovering the product, such as the polypeptide, from the cell, cell population or culture medium.
[0397] 46. The method of claim 45, comprising isolating the polypeptide, e.g., the recombinant polypeptide, from the cells or the culture medium in which the cells are cultured.
[0398] 47. The method of items 45-46, wherein the product comprises an antibody molecule (e.g., a monoclonal antibody), a bispecific molecule, a coagulation factor, an anticoagulant, a hormone, an interferon, an interleukin or an enzyme, for example, a polypeptide having the same amino acid sequence or differing from a polypeptide from Table 1 or Table 2 by no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues.
[0399] 48. The method of any one of items 1 to 47, further comprising any one of steps (f), (g), or both (f) and (g):
[0400] f) culturing the cell or cell progeny in the absence of the exogenous protein degradation inhibitor (e.g., for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more generations or for at least 12, 24, 48, 72 hours);
[0401] g) evaluating the level of recombinant protein produced by the cell or the progeny of the cell, e.g., to obtain a value for the recombinant protein produced by the cell or the progeny of the cell; and
[0402] h) optionally, comparing the value obtained in g) with said reference value, wherein said reference value is the level of the recombinant protein produced by cells of the same type as the cells provided in a) cultured in the absence of an exogenous protein degradation inhibitor.
[0403] 49. A method of producing a cell or cell progeny that produces a recombinant protein (e.g., a recombinant therapeutic protein, e.g., a recombinant therapeutic antibody), comprising:
[0404] a) optionally, providing cells;
[0405] b) culturing the cell or progeny of the cell (e.g., for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 or more generations or for at least 12, 24, 48, 72 hours or 1, 2, 4, 8, 16, 32 or more weeks) in the presence of an exogenous protein degradation inhibitor, such as a proteasome inhibitor, an ubiquitin pathway inhibitor, or an endoplasmic reticulum-associated degradation (ERAD) inhibitor;
[0406] c) culturing the cell or cell progeny in the absence of the exogenous protein degradation inhibitor (e.g., for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more generations or for at least 12, 24, 48, 72 hours);
[0407] d) optionally, evaluating the effect of the protein degradation inhibitor on the level of recombinant protein produced by the cell or the progeny of the cell, e.g., to obtain a value for the recombinant protein produced by the cell or the progeny of the cell; and
[0408] e) optionally, comparing the value obtained in d) with a reference value, wherein the reference value is the level of the recombinant protein produced by cells of the same type as the cells provided in a) cultured in the absence of the exogenous protein degradation inhibitor;
[0409] Thereby generating the cell or cell progeny.
[0410] 50. The method of claim 49, further comprising f) selecting the cell for use in producing a recombinant protein (eg, a recombinant therapeutic protein).
[0411] 51. The method of item 49 or 50, which also includes g) introducing exogenous nucleic acid into the cell (for example, after step c), after step d), after step e) or after step f)), optionally, wherein introducing the exogenous nucleic acid includes transfection, electroporation or transduction.
[0412] 52. A cell, progeny cell or population of progeny cells assessed, classified, selected or generated by the method of any one of items 1-51.
[0413] 53. The cell of item 52, wherein the cell is a eukaryotic cell, such as a cell according to any one of items 17-20.
[0414] 54. The cell of any one of items 52 or 53, wherein the cell comprises an exogenous nucleic acid that controls, e.g., increases, the expression of a product, e.g., a polypeptide, e.g., an endogenous polypeptide.
[0415] 55. The cell of item 54, wherein the product comprises a recombinant polypeptide, such as an antibody molecule (e.g., a monoclonal antibody or a bispecific antibody), a coagulation factor, an anticoagulant, a hormone, an interferon, an interleukin, an enzyme or a bispecific molecule, for example, a polypeptide having the same amino acid sequence or differing from a polypeptide from Table 1 or Table 2 by no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues.
[0416] 56. A product, such as a polypeptide, such as a recombinant polypeptide, produced or producible by the method of any one of items 1-51 or by the cell of any one of items 52-55.
[0417] 57. The product of item 56, such as a polypeptide, such as a recombinant polypeptide, wherein the product, such as a polypeptide, such as a recombinant polypeptide, comprises an antibody molecule, a coagulation factor, an anticoagulant, a hormone, an interferon, an interleukin, an enzyme or a bispecific molecule, for example, a polypeptide having the same amino acid sequence or differing from a polypeptide from Table 1 or Table 2 by no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues.
[0418] 58. A preparation comprising a product produced or producible by the method of any one of items 1-51 or by the cell of any one of items 52-55, such as a polypeptide, such as a recombinant polypeptide, optionally wherein at least 70, 80, 90, 95, 98 or 99% of the polypeptides in the preparation are properly folded or functionally active, by weight or number.
[0419] 59. A mixture comprising a cell and a product, such as a polypeptide, such as a recombinant polypeptide, according to any one of items 52 to 55, wherein:
[0420] The product, e.g., the polypeptide, e.g., the recombinant polypeptide, is present at a concentration higher by weight or number than that seen in cells that have not been contacted with the protein degradation inhibitor, e.g., at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more; or
[0421] wherein at least 70, 80, 90, 95, 98 or 99% by weight or number of the product, e.g., the polypeptide, e.g., the recombinant polypeptide, in the mixture is properly folded or functionally active.
[0422] 60. A medium formulation conditioned by a culture of a cell, progeny cell, or progeny cell population as described herein, e.g., a cell, progeny cell, or progeny cell population of any one of items 52-55, wherein
[0423] The product, e.g., the polypeptide, e.g., the recombinant polypeptide, is present at a concentration higher, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, or 30% higher, by weight or number, than the concentration seen in cells that have not been contacted with the protein degradation inhibitor; or
[0424] wherein at least 70, 80, 90, 95, 98 or 99% by weight or number of the product, e.g., the polypeptide, e.g., the recombinant polypeptide, in the mixture is properly folded or functionally active.
[0425] 61. A preparation or mixture as described in any of items 58-60, wherein the product comprises an antibody molecule, a coagulation factor, an anticoagulant, a hormone, an interferon, an interleukin, an enzyme or a bispecific molecule, for example, having the same amino acid sequence or differing from a polypeptide from Table 1 or Table 2 by no more than 1, 2, 3, 4, 5, 10, 15 or 20 amino acid residues.
Claims
1. A method for preparing a cell line having improved production capacity and / or producing a recombinant polypeptide product of improved quality, the method comprising: a) contacting the cell population with a first inhibitor of a protein degradation pathway, wherein the first inhibitor is a proteasome inhibitor, a ubiquitin pathway inhibitor, or an ERAD inhibitor; b) evaluating the effect of the inhibitor on the quantity of a polypeptide produced by one or more cells in the cell population, or on the quality of a polypeptide, as compared to cells of the same type not contacted with the inhibitor; c) selecting a cell or a progeny cell thereof if it has improved production of the polypeptide product and / or improved quality of the polypeptide product compared to a cell of the same type not contacted with the inhibitor; d) culturing the cell or progeny cells thereof to provide a cell line; e) introducing exogenous nucleic acid encoding the recombinant polypeptide product into the cell line; f) expressing said recombinant polypeptide product in said cell line; and wherein the production cell line expresses the recombinant polypeptide product in the absence of a first inhibitor of a protein degradation pathway; and Wherein the cell line is capable of producing a recombinant polypeptide product with increased productivity and / or increased quality compared to cells of the same type that have not been contacted with the inhibitor.
2. The method of claim 1, wherein the polypeptide in step (b) is a recombinant protein encoded by an exogenous nucleic acid.
3. The method of claim 1 or 2, wherein the amount of the polypeptide produced in step (b) in the presence of the inhibitor is increased compared to the level, amount or quantity produced by cells not contacted with the inhibitor and / or the improved quality of the product comprises one or more of: an improved level, amount, or ratio of a desired product, such as a ratio compared to an undesired isomer, fragmented or truncated form; Improved level, amount, or proportion of properly folded product; Improved level, amount, or functionality, such as the proportion of an enzymatically active product; reduced level, amount, or proportion of an aggregated product; or reduced level, amount, or proportion of fragmented or undesirable isomers.
4. The method of any one of claims 1 to 3, wherein the inhibitor is a proteasome inhibitor, optionally wherein the proteasome inhibitor inhibits or reduces the activity of one or more of the following: 20S core subunit, 19S regulatory subunit, 11S regulatory particle, or a chaperone protein that assists in proteasome assembly, such as Hsm3 / S5b, Nas2 / p27, Rpn14 / PAAF1, and Nas6 / gankyrin, optionally wherein the proteasome inhibitor is selected from MG132, epoxomicin, bortezomib, ixazomib, carfilzomib, disulfiram, CEP-18770, ONX 0912, salinosporamide, LLnV, CEP1612, lactacystin, PS-341, and eponomicin.
5. The method of any one of claims 1-3, wherein the inhibitor is an ERAD inhibitor, optionally wherein the ERAD inhibitor inhibits or reduces the activity of one or more of: calnexin / calreticulin, UDP-glucose-glycoprotein glucosyltransferase, ER degradation-enhancing α-mannosidase-like protein (EDEM), ER mannosidase I, Sec61, CDC48p (VCP / p97), Hrd1, Doa10, Ubc6, Ubc1, Cue1, or Ubc7, optionally wherein the protein degradation inhibitor is eeyarestatin I.
6. The method of any one of claims 1-3, wherein the inhibitor is a ubiquitin pathway inhibitor, optionally wherein the ubiquitin pathway inhibitor inhibits or reduces the activity of one or more of: an E1 ubiquitin activating enzyme, an E2 ubiquitin conjugating enzyme, or an E3 ubiquitin ligase.
7. The method of any one of claims 1 to 6, further comprising: The cell is contacted with a second protein degradation pathway inhibitor, optionally wherein the cell is contacted with a first and a second inhibitor of protein degradation, eg, simultaneously or sequentially.
8. The method of claim 7, wherein: (i) the first protein degradation inhibitor and the second protein degradation pathway inhibitor are selected from MG132, epoxomicin or eeyarestatin 1; (ii) the first inhibitor is a proteasome inhibitor, and the second inhibitor is a proteasome inhibitor; (iii) the first inhibitor is a proteasome inhibitor, and the second inhibitor is an ERAD inhibitor or a ubiquitin pathway inhibitor; (iv) the first inhibitor is an ERAD inhibitor, and the second inhibitor is an ERAD inhibitor; (v) the first inhibitor is an ERAD inhibitor, and the second inhibitor is a ubiquitin pathway inhibitor or a proteasome inhibitor; (vi) the first inhibitor is a ubiquitin pathway inhibitor and the second inhibitor is a ubiquitin pathway inhibitor; or (vii) the first inhibitor is a ubiquitin pathway inhibitor, and the second inhibitor is an ERAD inhibitor or a proteasome inhibitor.
9. The method of any one of claims 1-8, wherein the cells are contacted with a concentration of the protein degradation inhibitor sufficient to reduce culture viability by about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or 75%, e.g., compared to the viability of the culture prior to contacting the culture with the inhibitor, or compared to a culture not contacted with the inhibitor, optionally wherein the concentration of the protein degradation inhibitor is a concentration at which one or more cells continue to proliferate.
10. The method of any one of claims 1-9, wherein the concentration of the protein degradation inhibitor is less than 0.5 μM MG-132; or less than 0.05 μM epoxomicin.
11. The method of any one of claims 1-10, wherein the cells are contacted with the protein degradation inhibitor, such as cultured in the protein degradation inhibitor, for 24, 48, 72, 96 hours or more.
12. The method of any one of claims 1-11, wherein the cells are contacted with the protein degradation inhibitor before, 24, 48, 72, 96, or 168 hours after, or simultaneously or concurrently with the selection step.
13. The method of any one of claims 2-12, wherein the recombinant polypeptide is selected from the group consisting of an antibody molecule, a bispecific molecule, a coagulation factor, an anticoagulant, a hormone, an interferon, an interleukin, and an enzyme selected from Table 1 or 2.
14. The method of any one of claims 1-13, wherein the cell is a mammalian cell.
15. The method of any one of claims 1-14, wherein the cell is from a mouse, rat, Chinese hamster, Syrian hamster, monkey, human, dog, camel, horse, ferret, or cat.
16. The method of any one of claims 1-15, wherein the cell is a CHO cell.
17. The method of any one of claims 1 to 15, wherein the cell is selected from the group consisting of Hela, HEK293, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK, VERO, SP2 / 0, NS0, YB2 / 0, EB66, C127, L cells, COS, such as COS1 and COS7, QC1-3, CHOK1, CHOK1SV, Potelligent CHOK1SV, CHO GS knockout, CHOK1SV GS-KO, CHOS, CHO DG44, CHO DXB11, and CHOZN.
18. The method of any one of claims 1 to 17, wherein the polypeptide in step (b) is evaluated by a parameter associated with a physical or functional property, such as primary sequence, glycosylation, primary, secondary, tertiary or quaternary structure, activity, degree of glycosylation, degree of aggregation, the proportion or level of expression products having a preselected property, such as a preselected monomer, dimer or trimer structure, or the level or proportion of expression products having a preselected structure, such as a non-denatured or non-aggregated structure.
